Novel bispecific fusion protein and use thereof
Patent Information
- Application Number
- MYPI2025007937
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-12-22
AI Technical Summary
Current treatments for metabolic abnormality-related fatty liver disease and steatohepatitis lack effective drugs, and existing dual-specific fusion proteins are not adequately suited for these conditions, with GLP-1 and GLP-2 activities needing precise control for optimal metabolic disease treatment.
A dual-specific fusion protein is developed, where the activity of the GLP-1 analog is enhanced to 40% or more compared to wild-type GLP-1 and the activity of the GLP-2 analog is 50% or less compared to wild-type GLP-2, linked to the antibody Fc region for improved metabolic disease treatment, including obesity and type 2 diabetes.
The dual-specific fusion protein effectively treats metabolic diseases such as obesity, type 2 diabetes, and fatty liver disease by enhancing GLP-1 activity while controlling GLP-2 activity, demonstrating significant weight loss and metabolic improvements in animal models.
Smart Images

Figure PI2025007937_DRAWING_001 
Figure PI2025007937_DRAWING_002 
Figure PI2025007937_DRAWING_003
Abstract
Description
Novel dual-specificity fusion proteins and their uses
[0001] The present invention relates to a novel dual-specificity fusion protein and its use, and more particularly, to a dual-specificity fusion protein comprising a GLP-1 analogue and a GLP-2 analogue, wherein the activity of the GLP-1 analogue and the activity of the GLP-2 analogue are precisely controlled, and its use.
[0002] Both GLP-1 and GLP-2 are peptide hormones that are produced through a series of tissue-specific protein cleavage processes expressed as a precursor called proglucagon. Of these, GLP-1 is produced and secreted by enteroendocrine L cells in the small intestine and specific neurons in the nucleus of the solitary tract in the brainstem when food is ingested. The initial product, GLP-1(1-37), is easily amidated and converted to two truncated forms (GLP-1(7-36) amide and GLP-1(7-37)) with equally biological activities through cleavage. Since active GLP-1 plays a role in lowering blood sugar levels in a glucose-dependent manner, it has been developed and used as a treatment for type 2 diabetes. In addition, GLP-2, like GLP-1, is a 33 amino acid long peptide produced by a special post-translational cleavage process of proglucagon. It is produced in enteroendocrine L cells of the small intestine and various nerve cells of the central nervous system, and is secreted together with GLP-1 from the small intestine when food is ingested. GLP-2 is known to improve small intestine growth and function, reduce bone destruction, and have neuroprotective effects when administered, and is currently being developed as a treatment for diseases such as short bowel syndrome, Crohn's disease, and osteoporosis.
[0003] As mentioned above, GLP-1 originally attracted attention for its beneficial effects on glucose homeostasis in the treatment of patients with type 2 diabetes (Gutniaket et al., N. Engl. J. Med. 326: 1316-1322, 1992). However, similar to GLP-2, it has also been suggested to have a role in the treatment of short bowel syndrome through research results showing that it reduces gastric secretion and motility (Kunkelet et al., Neurogastroenterol. Motil. 23: 739-e328, 2011). In addition, it has been reported that activation of the GLP-1 receptor (GLP-1R) signaling pathway by GLP-1 promotes intestinal growth and fusion of small intestinal crypt cells (Koehler et al., Cell Metabol. 21(3): 379-391, 2015). Based on this mechanism, Naia is conducting a phase 1 clinical trial for short bowel syndrome using GLP-1-XTEN, which is a GLP-1 linked to XTEN, a half-life-extending peptide. Furthermore, it has been reported that co-administration of GLP-1 and GLP-2 showed an additive effect on intestinal absorption compared to administration of each peptide alone (Madsenet et al., Regul. Pept. 184: 30-39, 2013).
[0004] Meanwhile, metabolic dysfunction-associated steatotic liver disease (MASLD) is not a single disease, but rather includes various forms of liver disease ranging from simple fatty liver without inflammation to chronic hepatitis and cirrhosis, and is known to be closely related to obesity and resulting insulin resistance. MASLD can vary greatly in severity, from mild fatty liver disease with only fat accumulation and no liver cell damage, to steatohepatitis with severe and persistent liver cell damage, and even liver fibrosis or cirrhosis (liver cirrhosis) accompanied by ascites or jaundice. It is known to progress further and even lead to liver cancer. In addition, the incidence of MASLD is rapidly increasing as a Western-type disease due to the spread of Western eating habits. Although most cases of metabolic fatty liver disease are mild, one in four patients with severe fatty liver disease will develop cirrhosis (or fibrosis) over time if left untreated, so it is by no means a symptom that can be ignored. The prevalence of metabolic fatty liver disease varies depending on the characteristics of the population, ranging from 10-24% in the general population to 58-74% in obese individuals. However, there are currently no drugs approved for the treatment of metabolic fatty liver disease or metabolic steatohepatitis, making the development of a treatment for metabolic fatty liver disease an urgent task.
[0005] In this regard, the present inventors have developed a dual-specificity protein that simultaneously targets GLP-1R and GLP-2R (Korean Patent No. 10-2349718).
[0006] However, although the above-mentioned dual-specificity fusion protein can be used universally for various metabolic diseases such as short bowel syndrome, obesity, type 2 diabetes, and metabolic disorder-associated steatohepatitis, there is no disclosure at all about a form of dual-specificity fusion protein more suitable for metabolic diseases.
[0007] Accordingly, the present invention aims to solve various problems, including the problems described above, by providing a novel dual-specificity fusion protein that maintains the functions of GLP-1 and GLP-2 while possessing activity more suitable for the treatment of metabolic diseases. However, the scope of protection of the present invention is not limited to the above-mentioned purpose.
[0008] According to one aspect of the present invention, a dual specificity fusion protein is provided in which a GLP-1 analogue and a GLP-2 analogue are fused, wherein the activity of the GLP-1 analogue is 40% or more compared to wild-type GLP-1 (human GLP-1 peptide), and the activity of the GLP-2 analogue is 50% or less compared to wild-type GLP-2 (human GLP-2 peptide).
[0009] According to another aspect of the present invention, a bispecific fusion protein is provided, which comprises a first fusion protein in which a GLP-1 analogue is linked to an antibody Fc region and a second fusion protein in which a GLP-2 analogue is linked to an antibody Fc region, wherein the bispecific fusion protein is produced by dimerization of the first fusion protein and the second fusion protein, wherein the activity of the GLP-1 analogue is 40% or more compared to wild-type GLP-1 (human GLP-1 peptide), and the activity of the GLP-2 analogue is 50% or less compared to wild-type GLP-2 (human GLP-2 peptide).
[0010] According to one aspect of the present invention, a composition comprising the dual specificity fusion protein is provided.
[0011] According to another aspect of the present invention, a pharmaceutical composition for treating a metabolic disease is provided, comprising at least one of the above-mentioned dual-specificity fusion proteins as an active ingredient.
[0012] According to another aspect of the present invention, any one of the above dual specificity fusion proteins for use in the treatment of metabolic diseases is provided.
[0013] According to another aspect of the present invention, there is provided a use of any one of the above dual specificity fusion proteins in the manufacture of a therapeutic agent for metabolic diseases.
[0014] According to another aspect of the present invention, a method of treating a metabolic disease in a subject is provided, comprising administering to the subject a therapeutically effective amount of the dual specificity fusion protein.
[0015] The dual-specificity fusion protein of the present invention can be very effectively used for the treatment of metabolic diseases such as metabolic syndrome, obesity, type 1 diabetes, type 2 diabetes, metabolic disorder-associated fatty liver disease, and liver fibrosis when administered in vivo.
[0016] FIG. 1 is a schematic diagram showing the schematic structure of a dual-specificity fusion protein according to one embodiment of the present invention.
[0017] Figure 2a is a series of gel photographs showing the results of SDS-PAGE analysis under non-reducing (NR) and reducing (R) conditions after purification of a comparative example of the present invention, GLP-2 homodimer (GLP-2-Fc homodimer, left) and MG12-5 containing a Knobs-into-Holes structure (right):
[0018] M: size marker;
[0019] 1 & 2: GLP-2-Fc homo(10 μg); and
[0020] 3 & 4: MG12-5 (10 μg).
[0021] Figure 2b is a series of gel photographs showing the results of SDS-PAGE analysis of MG12-6 under reducing and non-reducing conditions according to one embodiment of the present invention:
[0022] M: size marker;
[0023] 1: MG12-6; and
[0024] C: Ctrl (3 μg)-Herceptin.
[0025] Figure 2c is a series of gel photographs showing the results of SDS-PAGE analysis of MG12-7 and MG12-8 under reducing and non-reducing conditions according to one embodiment of the present invention:
[0026] M: size marker;
[0027] 1: MG12-7;
[0028] 2: MG12-8; and
[0029] 3: Ctrl (3 μg)-Herceptin.
[0030] Figure 2d is a gel photograph showing the results of SDS-PAGE analysis of MG12-9 under reducing and non-reducing conditions according to one embodiment of the present invention:
[0031] 1: Reducing MG12-9;
[0032] 2: Non-reducing MG12-9; and
[0033] 3: Ctrl (3 μg)-BSA.
[0034] FIG. 3a is a schematic diagram schematically showing an experimental schedule, drug dosage, administration interval, etc. for analyzing the weight loss effect upon single administration of a dual-specificity fusion protein (MG12-8) according to an embodiment of the present invention. FIG. 3b is a graph showing the change in body weight of experimental animals as a result of an experiment performed according to the schedule of FIG. 3a. FIG. 3c is a schematic diagram schematically showing an experimental schedule, drug dosage, administration interval, etc. for analyzing the weight loss effect upon repeated administration of a dual-specificity fusion protein (MG12-8) according to an embodiment of the present invention. FIG. 3d is a graph showing the change in body weight of experimental animals as a result of an experiment performed according to the schedule illustrated in FIG. 3c. FIG. 3e is a graph showing the results of measuring the volume of the gallbladder of experimental animals sacrificed after the end of the experiment of FIG. 3d. NS indicates statistically not significant, ** indicates statistical significance of p<0.01, and the error bar indicates the standard error of the mean (SEM).
[0035] Figure 4a is a schematic diagram showing an experimental schedule, drug dosage, administration interval, etc. for verifying the therapeutic effect of a dual-specificity fusion protein on fatty liver disease associated with metabolic abnormalities accompanied by intestinal leakiness according to one embodiment of the present invention. Figure 4b is a graph showing the body weight of experimental animals measured after the end of the animal experiment performed according to the schedule shown in Figure 4a. Figure 4c is a graph showing the results of measuring the serum fluorescence level of FITC-Dextran orally administered 4 hours before the sacrifice of the experimental animal of Figure 4b.
[0036] FIG. 5a is a graph showing the results of analyzing the in vitro GLP-1 activity of various samples of dual-specific fusion proteins manufactured according to one embodiment of the present invention. FIG. 5b is a schematic diagram showing the schedule of an intraperitoneal administration glucose tolerance test experiment, the dosage of administered drugs, the administration interval, etc. for analyzing the in vivo GLP-1 activity of various samples of dual-specific fusion proteins having in vitro GLP-1 activity according to one embodiment of the present invention. FIG. 5c is a graph showing the results of an intraperitoneal administration glucose tolerance test performed according to the schedule shown in FIG. 5b. In the above graphs, * indicates statistical significance at the p<0.05 level, and ** indicates statistical significance at the p<0.01 level.
[0037] FIG. 6a is a series of graphs showing the results of measuring the rate of body weight change (left) and the rate of change in the fat-to-fat ratio (right) according to administration of a dual-specificity fusion protein according to an embodiment of the present invention, in comparison with Dapiglutide mimetic, a known GLP-1R / GLP-2R dual agonist. FIG. 6b is a graph showing the change in the rate of body weight change according to the administration dose of a dual-specificity fusion protein according to an embodiment of the present invention. FIG. 6c is a graph showing the results of analyzing the effect of a dual-specificity fusion protein according to an embodiment of the present invention on body weight change compared to simple co-administration of the same dose of GLP-1-Fc and GLP-2-Fc. FIG. 6d is a graph showing the rate of body weight change in a diet-induced obesity model animal induced by a high-fat diet of a dual-specificity fusion protein according to an embodiment of the present invention, in comparison with Tirzepatide mimetic, a GLP-1R / GLP-2R dual agonist. Figure 6e is a graph showing the results of measuring the rate of change in the weight of adipose tissue of an experimental animal in the experiment of Figure 6d. Figure 6f is a graph showing the results of measuring the rate of change in the weight of non-adipose tissue of an experimental animal in the experiment of Figure 6d. Figure 6g is a graph showing the results of measuring the subcutaneous fat percentage (left) and visceral fat percentage (right) of a dual-specificity fusion protein according to one embodiment of the present invention in a diet-induced obesity model animal in which obesity is induced by a high-fat diet. Tirzepatide mimetic was used as a positive control. In the above graphs, NS indicates statistically not significant, * indicates statistical significance at the p<0.05 level, and ** indicates statistical significance at the p<0.01 level.
[0038] Figure 7a is a graph showing the results of measuring the serum LPS concentration for analyzing the endotoxemia reduction effect in a diet-induced obesity model animal induced by a high-fat diet of a dual-specificity protein according to one embodiment of the present invention. Figure 7b is a graph showing the results of measuring the serum ALT concentration for analyzing the liver damage inhibition effect in the experimental animal of Figure 7a. In the above graphs, * indicates statistical significance at the p<0.05 level, and ** indicates statistical significance at the p<0.01 level.
[0039] FIG. 8 is a series of graphs showing the results of an insulin-stimulated glucose uptake analysis of a dual-specificity fusion protein according to one embodiment of the present invention, including (a) normalized mean fluorescence intensity measuring the surface expression level of GLP-1R and GLP-2R of differentiated 3T3-L1 adipocytes, (b, c) normalized mean fluorescence intensity measuring the surface expression level of GLP-1R and GLP-2R of differentiated L6-GLUT4myc myoblasts, and (e, f) normalized mean fluorescence intensity measuring the surface expression level of GLP-1R and GLP-2R of differentiated L6-GLUT4myc myoblasts. In the above graphs, * indicates statistical significance at the p< 0.05 level, and ** indicates statistical significance at the p< 0.01 level.
[0040] FIG. 9 is a series of graphs showing the effects of administration of a dual-specificity fusion protein according to one embodiment of the present invention on blood glucose enhancement, changes in glycated hemoglobin, and insulin resistance, showing (a) non-fasting blood glucose levels, (b) glycated hemoglobin (HbA1c) levels, (c) fasting blood glucose levels, (d) fasting insulin concentrations, (e) HOMA-IR scores, and (f) HOMA-β scores. In the graphs, * indicates statistical significance at the p< 0.05 level, and ** indicates statistical significance at the p< 0.01 level.
[0041] Figure 10 shows the results of histological analysis of the pancreas removed after the experiment of Figure 9, (a-c) micrographs showing the results of immunohistochemical analysis of the pancreatic tissue section staining (a) insulin, (b) insulin and glucagon, (c) insulin and Ki-67 positive cells, and (d) islet area, (e) beta-cell area, (f) alpha-cell area, (g) beta- / alpha-cell ratio, and (h) 10,000 μm 2 This graph shows the number of Ki-67 positive cells per group. In the above graphs, * indicates statistical significance at the p<0.05 level, and ** indicates statistical significance at the p<0.01 level.
[0042] Definition of terms:
[0043] The term "GLP-1" as used in this document is an abbreviation for "glucagon-like peptide-1", a 30 or 31 amino acid peptide hormone derived from the tissue-specific post-translational processing of the proglucagon peptide. GLP-1 is produced and secreted by enteroendocrine L cells of the small intestine and specific neurons within the nucleus of the solitary tract of the brainstem upon food ingestion. The primary product, GLP-1(1-37), is readily amidated and converted by cleavage into two truncated forms with equally biological activity: GLP-1(7-36) amide and GLP-1(7-37). Active GLP-1 contains two alpha-helical regions at amino acid positions 13-20 and 24-35, and a linker region connecting the two alpha-helical regions. Because GLP-1 lowers blood sugar levels in a glucose-dependent manner, it has been developed and used as a treatment for type 2 diabetes. However, GLP-1 is rapidly degraded in vivo by dipeptidyl peptidase-4 (DPP-4), resulting in a half-life of only two minutes. Therefore, its efficacy as a natural peptide is extremely limited.
[0044] The term "GLP-2" used in this document refers to a 33-amino acid peptide produced by the post-translational cleavage process of proglucagon, similar to GLP-1, in the enteroendocrine L cells of the small intestine and various nerve cells in the central nervous system. GLP-2 is secreted together with GLP-1 when food is ingested. GLP-2 is known to improve small intestinal growth and function, reduce bone destruction, and have neuroprotective effects when administered, and is currently being developed as a treatment for diseases such as short bowel syndrome, Crohn's disease, and osteoporosis.
[0045] The term "GLP-1 analogue" as used in this document refers to a protein that biologically performs the function of GLP-1 and can bind to the GLP-1 / Exendin-4 receptor and mediate downstream signaling, and is also referred to as a "GLP-1 receptor agonist."
[0046] The term "GLP-2 analogue" as used in this document refers to a protein that biologically performs the function of GLP-2 and can bind to the GLP-2 receptor and mediate downstream signaling, and is also referred to as a "GLP-2 receptor agonist."
[0047] The term "fusion protein" used in the present invention refers to a recombinant protein in which two or more proteins or domains responsible for specific functions within a protein are linked so that each protein or domain performs its original function.
[0048] The term "half-life increasing moiety" as used in this document refers to a functional group linked to a recombinant protein to improve the half-life of the recombinant protein in vivo. Such "half-life increasing moieties" include antibody Fc regions (Caponet et al., Nature. 337: 525-531, 1989), PEG (Caliceti and Veronese, Adv. Drug Delivery Rev. 55: 1261-1277, 2003), XTEN (Schellenberger et al., Nat. Biotechnol. 27: 1186-1190, 2009), PAS (Pro-Ala-Ser, Schlapschy et al., Protein Eng. Des. Sel. 26: 489-501, 2013), ELP (elastine-like peptide, Flosset et al., Trends Biotechnol. 28: 37-45, 2010), and glycine-rich HAP (homo-amino-acid polymer, Schlapschyet al., Protein Eng. Des. Sel. 20: 273-284, 2007), GLK (gelatine-like protein, Huang et al., Eur. J. Pharm. Biopharm. 74(3): 435-441, 2010), and serum albumin (Sheffield et al., Cell Physiol. Biochem., 45(2): 772-782, 2018) can be used, and the "half-life increasing moiety" added to such proteins is well known through review papers, etc. (Strohl, WR, BioDrugs, 29(4): 215-239, 2015). Therefore, prior papers on the above individual factors and the above review papers are incorporated herein by reference.
[0049] The term "antibody Fc region" as used in this document refers to the crystallized fragment produced when an antibody is cleaved with papain, which interacts with cell surface receptors called Fc receptors and some proteins of the complement system. The Fc region exhibits a homodimeric structure in which fragments containing the second and third constant domains (CH2 and CH3) of the heavy chain are linked by intermolecular disulfide bonds at the hinge region. The Fc region of IgG contains multiple N-glycan attachment sites, which are known to play an important role in Fc receptor-mediated interactions.
[0050] The term "hybrid Fc region" as used in this document refers to an Fc region peptide generated by combining portions of Ig Fc regions of various subtypes, and which can exhibit differences from the wild-type Fc region in binding ability to Fc receptors and complement due to the combination of these Fc region portions.
[0051] The term "Exendin" used in this document refers to a 39-amino acid peptide isolated from the venom of the lizard Heloderma suspectum. Exendin 4 is 50% identical in amino acid sequence to GLP-1 and, as a member of the glucagon peptide family, is known to perform a role equivalent to GLP-1 as an agonist of the GLP-1 receptor. Exendin 4 is also called "extenatide." Exendin 3 is a mutant of Exendin 4 in which the second and third amino acids are substituted with serine and aspartic acid, respectively.
[0052] The term "Lixisenatide" used in this document is a GLP-1 receptor agonist, manufactured by Sanofi and sold in Europe under the brand name Lyxumia and in the United States under the brand name Adlyxin, as a daily injection for the treatment of type 2 diabetes.
[0053] The term "Albiglutide" used in this document refers to one of the GLP-1 receptor agonists marketed by GSK in Europe under the brand name Eperzan and in the United States under the brand name Tanzeum for the treatment of type 2 diabetes.
[0054] The term "Liraglutide" as used in this document refers to a subcutaneous GLP-1 receptor agonist marketed by Novo Nordisk under the brand name "Victoza" for the treatment of type 2 diabetes and obesity.
[0055] The term "Taspoglutide" used in this document refers to a GLP-1 receptor agonist jointly developed by Ipsen and Roche for the treatment of type 2 diabetes. It is a GLP-1 derivative in which the 8th and 35th amino acids of the GLP-1(7-36) peptide, alanine, are methylated and the final amino acid is amidated. However, when manufactured in the form of a fusion protein with another peptide, the C-terminus may not be amidated and may be a general carboxyl group.
[0056] The term "Semaglutide" used in this document is a GLP-1R agonist, an oral hypoglycemic agent used to treat type 2 diabetes and an anti-obesity agent used for long-term weight management. It is a drug developed by Novo Nordisk in 2012 and approved for sale in the United States in 2017.
[0057] The term "Tirzepatide" used in this document is a type of GLP-1R agonist, currently used for the treatment of type 2 diabetes and weight loss, and is a drug developed by Eli Lilly and approved for sale in the United States in 2022.
[0058] The term "Dapiglutide" used in this document refers to a GLP-1R and GLP-2R dual agonist developed by Zealand Pharma, which is currently in phase 1 clinical trials.
[0059] The term "XTEN" used in this document refers to an unstructured, low-immunogenic peptide containing six amino acids added to improve the in vivo half-life of protein pharmaceuticals developed by Amunix, and is typically composed of amino acids in multiples of 144 aa as a unit (US2010 / 0239554A1).
[0060] The term "Teduglutide" used in this document is a GLP-2 analogue that is a mutant in which the second amino acid of GLP-2, alanine (A), is replaced with glycine (G). It is sold as a treatment for short bowel syndrome under the brand name Gattex in the United States and under the brand name Revestive in Europe.
[0061] The term "Glepaglutide" used in this document is a GLP-2 analogue with an improved half-life, which has been developed as a treatment for short bowel syndrome and is currently undergoing phase 3 clinical trials for short bowel syndrome.
[0062] The term "GLP-2 analogue 10" used in this document refers to one of the GLP-2 analogues, which is characterized by having a stabilized structure by substituting the 11th and 18th amino acids of GLP-2 with cysteines, linking a lipidated intramolecular cross-linker through the thiol groups of the two substituted cysteines, and adding the C-terminal nine amino acids of Exendin 4 to the C-terminus (Yang et al., J. Med. Chem. 61: 3218-3223, 2018).
[0063] The term "linker peptide" as used in this document is an unstructured peptide used when preparing a fusion protein by linking two or more proteins or peptides with different biological activities.
[0064] The term "metabolic disorder" used in this document is a general term for diseases that occur when the metabolic process, which is a series of processes that obtain energy from the food consumed in the body, is abnormal. In particular, diseases such as obesity and diabetes that are caused by failure to regulate carbohydrate metabolism are representative. Various causes such as genetic and environmental factors have been suggested as the cause of these metabolic diseases, and recently, in addition to genetic factors, a carbohydrate-centered diet has been pointed out as the main cause. These metabolic diseases include diabetes such as type 1 diabetes and type 2 diabetes, obesity, metabolic syndrome, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, and liver cirrhosis.
[0065] The term "metabolic syndrome" used in this document refers to a disease presumed to be caused by insulin resistance, characterized by abnormalities in two or more of the following: cholesterol, blood pressure, and blood sugar levels. It conceptualizes the clustering of risk factors for various cardiovascular diseases and type 2 diabetes as a single disease group. It is a useful concept that encompasses insulin resistance (IR) and the complex and diverse metabolic abnormalities and clinical manifestations associated with it. If left untreated, metabolic syndrome is known to increase the risk of developing cardiovascular diseases such as arteriosclerosis, myocardial infarction, and stroke, as well as type 2 diabetes.
[0066] Detailed description of the invention:
[0067] According to one aspect of the present invention, a dual specificity fusion protein is provided in which a GLP-1 analogue and a GLP-2 analogue are fused, wherein the activity of the GLP-1 analogue is 40% or more compared to wild-type GLP-1 (human GLP-1 peptide), and the activity of the GLP-2 analogue is 50% or less compared to wild-type GLP-2 (human GLP-2 peptide).
[0068] According to another aspect of the present invention, a bispecific fusion protein is provided, which comprises a first fusion protein in which a GLP-1 analogue is linked to an antibody Fc region and a second fusion protein in which a GLP-2 analogue is linked to an antibody Fc region, wherein the bispecific fusion protein is produced by dimerization of the first fusion protein and the second fusion protein, wherein the activity of the GLP-1 analogue is 40% or more compared to wild-type GLP-1 (human GLP-1 peptide), and the activity of the GLP-2 analogue is 50% or less compared to wild-type GLP-2 (human GLP-2 peptide).
[0069] In the above dual specificity fusion protein, the activity of the GLP-1 analogue is preferably 41% or more, or 42% or more, or 43% or more, or 44% or more, or 45% or more, or 46% or more, or 47% or more, or 48% or more, or 49% or more, or 50% or more, 51% or more, or 52% or more, or 53% or more, or 54% or more, or 55% or more, or 56% or more, or 57% or more, or 58% or more, or 59% or more, or 60% or more, or 61% or more, or 62% or more, or 63% or more, or 64% or more, or 65% or more, or 66% or more, or 67% or more, or 68% or more, or 69% or more, or 70% or more, It means that it can have an activity of 71% or more, or 72% or more, or 73% or more, or 74% or more, or 75% or more, or 76% or more, or 77% or more, or 78% or more, or 79% or more, or 80% or more, or 81% or more, or 82% or more, or 83% or more, or 84% or more, or 85% or more, or 86% or more, or 87% or more, or 88% or more, or 89% or more, or 90% or more, or 91% or more, or 92% or more, or 93% or more, or 94% or more, or 95% or more, or 96% or more, or 97% or more, or 98% or more, or 99% or more, or 100% or more, and may have an activity of 100% or more but not more than 400%.
[0070] More specifically, the activity of the GLP-1 analogue is 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, It can be 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, or 120%, and can have a certain range with any value among the above percentages as the lower limit and another value greater than that as the upper limit.
[0071] In addition, the activity of the GLP-1 analogue can optionally exceed 120% compared to wild-type GLP-1 under in vitro conditions, and more specifically, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%, 176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%, 188%, 189%, 190%, 191%, 192%, 193%, 194%, 195%, 196%, 197%, 198%, 199%, 200%, 201%, 202%, 203%, 204%, 205%, 206%, 207%, 208%, 209%, 210%, 211%, 212%, 213%, 214%, 215%, 216%, 217%, 218%, 219%, 220%, 221%, 222%, 223%, 224%, 225%, 226%, 227%, 228%, 229%, 230%, 231%, 232%, 233%, 234%, 235%, 236%, 237%, 238%, 239%, 240%, 241%, 242%, 243%, 244%, 245%, 246%, 247%, 248%, 249%, 250%, 251%, 252%, 253%, 254%, 255%, 256%, 257%, 258%, 259%, 260%, 261%, 262%, 263%, 264%, 265%, 266%, 267%, 268%, 269%, 270%, 271%, 272%,273%, 274%, 275%, 276%, 277%, 278%, 279%, 280%, 281%, 282%, 283%, 284%, 285%, 286%, 287%, 288%, 289%, 290%, 291%, 292%, 293%, 294%, 295%, 296%, 297%, 298%, 299%, 300%, 301%, 302%, 303%, 304%, 305%, 306%, 307%, 308%, 309%, 310%, 311%, 312%, 313%, 314%, 315%, 316%, 317%, 318%, 319%, 320%, 321%, 322%, 323%, 324%, 325%, 326%, 327%, 328%, 329%, 330%, 331%, 332%, 333%, 334%, 335%, 336%, 337%, 338%, 339%, 340%, 341%, 342%, 343%, 344%, 345%, 346%, 347%, 348%, 349%, 350%, 351%, 352%, 353%, 354%, 355%, 356%, 357%, 358%, 359%, 360%, 361%, 362%, 363%, 364%, 365%, 366%, 367%, 368%, 369%, 370%, 371%, 372%, 373%, 374%, 375%, 376%, 377%, 378%, 379%, 380%, 381%, 382%, 383%, 384%, 385%, 386%, 387%, 388%, 389%, 390%, 391%, 392%, 393%, 394%, It can be 395%, 396%, 397%, 398%, 399%, or 400%, and can exceed 400%. In addition, the GLP-1 activity in vitro of the dual specificity fusion protein according to one embodiment of the present invention can have a certain range with any value among the above percentages as the lower limit and another value greater than that as the upper limit.
[0072] In the above dual specificity fusion protein, the activity of the GLP-2 analogue under in vitro conditions may be 2% or more compared to wild-type GLP-2.
[0073] In the above dual specificity fusion protein, the activity of the GLP-2 analogue is 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, It may be 46%, 47%, 48%, 49%, or less than or equal to 50%, and may have a certain range with any of the above percentages as the lower limit and another value greater than that as the upper limit.
[0074] The above dual specificity fusion protein may have a half-life increasing moiety added thereto, and the half-life increasing moiety may be inserted between the GLP-1 analogue and the GLP-2 analogue or added to the N-terminus or C-terminus of the entire fusion protein, and preferably may be an antibody Fc region, PEG, XTEN, PAS (Pro-Ala-Ser), ELP (elastin-like peptide), glycine-rich HAP (homo-amino-acid polymer), GLP (gelatine-like protein), or serum albumin.
[0075] The above-mentioned dual-specificity fusion protein may not be a proglucagon or an analogue thereof in which GLP-1 and GLP-2, which are naturally expressed in the body, are linked by an intermediate peptide (intervention peptide), but may be a fusion protein in which a GLP-1 analogue and a GLP-2 analogue are directly linked or the two peptides are linked by a linker peptide of a different form than the intermediate peptide.
[0076] In the above bispecific fusion protein, the GLP-1 analogue may be GLP-1, Exendin 3, Exendin 4, a GLP-1 / Exendin 4 hybrid peptide, GLP-1-XTEN, Exendin 4-XTEN, Lixisenatide, Albiglutide, Liraglutide, or Taspoglutide, or a contiguous repeat in which any one or more of these are linked. The contiguous repeat may increase GLP-1 activity or increase its length, thereby enabling quality control related to the production of the bispecific protein (making it easy to distinguish whether the produced protein is a heterodimer or a homodimer), and may simplify the manufacturing process compared to PEGylation, which is well known as a conventional half-life increasing technology, thereby having the advantage of reducing production costs. The number of repeating units of the contiguous repeat of the GLP-1 analogue may be adjusted according to the required GLP-1 activity.
[0077] In the above dual specificity fusion protein, the GLP-1 may include an amino acid sequence represented by SEQ ID NO: 1 or 2.
[0078] In the above dual specificity fusion protein, Exendin 3 may include an amino acid sequence represented by SEQ ID NO: 3.
[0079] In the above dual specificity fusion protein, Exendin 4 may be composed of an amino acid sequence represented by SEQ ID NO: 4.
[0080] In the above dual specificity fusion protein, the GLP-1 / Exendin 4 hybrid may include an amino acid sequence represented by SEQ ID NO: 5.
[0081] In the above dual specificity fusion protein, the Lixisenatide may include an amino acid sequence represented by SEQ ID NO: 6.
[0082] In the above dual specificity fusion protein, the Exendin 4-XTEN may include an amino acid sequence represented by SEQ ID NO: 7.
[0083] In the above dual specificity fusion protein, the Albiglutide may include an amino acid sequence represented by SEQ ID NO: 8.
[0084] In the above dual specificity fusion protein, the Liraglutide may include an amino acid sequence represented by SEQ ID NO: 9.
[0085] In the above dual specificity fusion protein, the Taspoglutide may include an amino acid sequence represented by SEQ ID NO: 10.
[0086] In the above dual specificity fusion protein, the GLP-1 tandem repeats may include an amino acid sequence represented by SEQ ID NO: 11.
[0087] In the above dual specificity fusion protein, the antibody Fc region may be an antibody Fc region in which a heterodimerization moiety is formed, and the dimerization moiety is Knobs-into-Holes (KiH), KiH S-S . HA-TF, ZW1, 7.8.60, DD-KK, EW-RVT, EW-RVT S-S , SEED or A107.
[0088] The term "Knobs-into-Holes (KiH)" as used in this document refers to a design strategy in antibody engineering used for heterodimerization of heavy chains in the production of recombinant proteins or IgG antibodies containing an Fc region. The above KiH technology, when the two fusion proteins forming the heterodimer are divided into a first fusion protein and a second fusion protein, the first fusion protein may be one in which the 22nd amino acid, threonine (T), of the CH3 domain in the first modified Fc region is substituted with tryptophan (W) (T366W) (Knob), the second fusion protein may be one in which the 22nd amino acid, threonine (T), of the CH3 domain in the second modified Fc region is substituted with serine (S) (T366S), the 24th amino acid, leucine (L), is substituted with alanine (A) (L368A), and the 63rd amino acid, tyrosine (Y), is substituted with valine (V) (Y407V) (Hole structure), and conversely, the first fusion protein may be one in which the 22nd amino acid, threonine (T), of the CH3 domain in the first modified Fc region is substituted with The second fusion protein may be one in which the 24th amino acid, leucine (L), is substituted with alanine (A) (L368A), and the 62nd amino acid, tyrosine (T), is substituted with valine (V) (Y407V) (Hole structure), and the second fusion protein may be one in which the 22nd amino acid, threonine (T), of the CH3 domain in the second modified Fc region is substituted with tryptophan (W) (T366W) (Knob structure).
[0089] At this time, the position of the amino acid in which the mutation occurred is based on positions 224-330 (SEQ ID NO: 61) corresponding to the CH3 region of the amino acid sequence of human IgG1 of UniProt No. P01857, and the numbers related to specific amino acid substitutions in parentheses are according to the EU numbering rules related to the amino acid sequence of the antibody. Even if additional mutations such as addition, deletion or substitution of amino acids occur in a site unrelated to the Knobs-into-Holes structure on the CH3 domain, the amino acid corresponding to the corresponding position can be used based on the reference sequence. Optionally, the Knobs-into-Holes structure can be introduced through other amino acid mutations well known in the art. These mutations are well described in the literature (Weiet et al., Oncotarget8(31): 51037-51049, 2017; Ridgway et al., Protein Eng. 9(7): 617-621, 1996; Carter, P., J. Immunol. Methods48(1-2): 7-15, 2001). These selective mutations can generate a dual-specificity dimeric fusion protein through a combination of, for example, a Knob structure in which threonine (T), the 22nd amino acid of the CH3 domain of the first fusion protein, is substituted with tyrosine (Y) (T366Y) and a Hole structure in which tyrosine (Y), the 63rd amino acid of the CH3 domain of the second fusion protein, is substituted with threonine (T) (Y403T). The above Knobs-into-Holes structure can be formed, conversely, by introducing a Hole structure into the first fusion protein and a Knob structure into the second fusion protein.
[0090] The term "KiH" used in this document S-S"is a structure in which cysteine is introduced into CH3 so that an intramolecular disulfide bond can be formed in the KiH structure, and in the KiH structure, the 10th amino acid of CH3 of Knob Fc, serine (S), is additionally substituted with cysteine (C) (S354C) and the 5th amino acid of Hole Fc, tyrosine (Y), is additionally substituted with cysteine (C) (Y349C) (Merchant et al., Nat. Biotechnol. 16(7): 677-681, 1998).
[0091] The term "HA-TF" used in this document refers to a technology that induces heterodimerization by utilizing hydrophobic / steric complementarity by substituting serine (S), the 20th amino acid of CH3 of the first modified Fc region, with histidine (H) (S364H), phenylalanine (F), the 61st amino acid, with alanine (A) (F405A), and tyrosine (Y), the 5th amino acid of CH3 of the second modified Fc region, with threonine (T) (Y349T), and threonine (T), the 50th amino acid, with phenylalanine (F) (T394F) (Moore et al., MAbs3(6): 546-557, 2011).
[0092] The term "ZW1" used in this document refers to a first variant Fc region CH3 in which the 6th amino acid, threonine (T), is substituted with valine (V) (T350V), the 7th amino acid, leucine (L), is substituted with tyrosine (Y) (L351Y), the 61st amino acid, phenylalanine (F), is substituted with alanine (A) (F405A), and the 63rd amino acid, tyrosine (Y), is substituted with valine (V) (Y407V), and the 6th amino acid, threonine (T), is substituted with valine (V) (T350V), the 22nd amino acid, threonine (T), is substituted with tryptophan (W) (T366W), the 48th amino acid, lysine (K), is substituted with leucine (L) (K392L), and the 50th amino acid, threonine (T). It refers to a technology that induces heterodimerization by utilizing hydrophobic / steric complementarity by substituting tryptophan (W) (T394W) (von Kreudensteinet al., MAbs5(5): 646-654, 2013).
[0093] The term "7.8.60" used in this document refers to a hydrophobic / stereotypic variant in which the 16th amino acid, lysine (K), of CH3 of the first variant Fc region is replaced with aspartic acid (D) (K360D), the 55th amino acid, aspartic acid (D), is replaced with methionine (M) (D399M), and the 63rd amino acid, tyrosine (Y), is replaced with valine (V) (Y407V), and the 1st amino acid, glutamic acid (E), of CH3 of the second variant Fc region is replaced with arginine (R) (E345R), the 3rd amino acid, glutamine (Q), is replaced with arginine (R) (Q347R), the 22nd amino acid, threonine (T), is replaced with valine (V) (T366V), and the 63rd amino acid, lysine (K), is replaced with valine (V) (K409V). It refers to a technique that induces heterodimerization using hydrophobic / steric complementarity and electrostatic complementarity (Leaver-Fayet al., Structure24(4): 641-651, 2016).
[0094] The term "DD-KK" used in this document refers to a technique for inducing heterodimerization using electrostatic complementarity by substituting lysine (K), the 65th amino acid of CH3 of the first modified Fc region, with aspartic acid (D) (K409D), lysine (K), the 48th amino acid, with aspartic acid (D) (K392D), as well as substituting aspartic acid (D), the 55th amino acid of CH3 of the second modified Fc region, with lysine (K) (D399K), and glutamic acid (E), the 13th amino acid, with lysine (K) (E356K) (Gunasekaranet al., J. Biol. Chem. 285(25): 19637-19646, 2010).
[0095] The term "EW-RVT" used in this document refers to a technique for inducing heterodimerization by utilizing hydrophobic / steric complementarity and long-range electrostatic interaction by substituting lysine (K), the 16th amino acid of CH3 of the first modified Fc region, with glutamic acid (E) (K360E), lysine (K), the 65th amino acid, with tryptophan (W) (K409W), glutamine (Q), the 3rd amino acid of CH3 of the second modified Fc region, with arginine (R) (Q347R), aspartic acid (D), the 55th amino acid, with valine (V) (D399V), and phenylalanine (F), the 61st amino acid, with threonine (T) (F405T) (Choi et al., Mol. Cancer Ther.12(12): 2748-2759, 2013).
[0096] The term "EW-RVT" used in this document S-S "is a structure in which cysteine is introduced into CH3 so that an intramolecular disulfide bond can be formed in the EW-RVT structure, and means that the 5th amino acid of CH3 of the first modified Fc region of the EW-RVT, tyrosine (Y), is additionally substituted with cysteine (C) (Y349C), and the 10th amino acid of CH3 of the second modified Fc region, serine (S), is additionally substituted with cysteine (C) (S354C) (Choi et al., Mol. Immunol. 65(2): 377-383, 2015).
[0097] The term "SEED" used in this document refers to a technique for inducing heterodimerization by utilizing hydrophobic / steric complementarity resulting from chain exchange between IgG and IgA by introducing 45 IgA-derived residues into CH3 of the first variant Fc region and 57 IgG1-derived residues into CH3 of the second variant Fc region (Daviset et al., Protein Eng, Des, Sel, 23(4): 195-202, 2010).
[0098] The term "A107" used in this document refers to a technique for inducing heterodimerization by utilizing hydrophobic / steric complementarity and hydrogen bonding complementarity by substituting lysine (K), the 26th amino acid of CH3 of the first variant Fc region, with glutamic acid (E) (K370E), lysine (K), the 69th amino acid, with tryptophan (W) (K409W), glutamic acid (E), the 13th amino acid of CH3 of the second variant Fc region, with asparagine (N) (E357N), aspartic acid (D), the 55th amino acid, with valine (V) (D399V), and phenylalanine (F), the 61st amino acid, with threonine (T) (F405T) (Choi et al., PLoS One10(12): e0145349, 2015).
[0099] The hybrid antibody Fc region may be composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 16. In addition, the hybrid antibody Fc region may be additionally mutated so as not to cause undesirable side effects upon administration into the body, such as antibody-dependent cell cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Such a hybrid antibody Fc region may be as described in Korean Patent No. 897938, and may be a hybrid Fc region variant (NTIG Knob) as described in SEQ ID NO: 15, in which the 18th amino acid, threonine (T), of the hybrid Fc region (Knob structure) consisting of the amino acid sequence represented by SEQ ID NO: 14 is substituted with glutamine (Q) and the 196th amino acid, methionine (M), is substituted with leucine (L), or a hybrid Fc region variant (NTIG Hole) as described in SEQ ID NO: 16, in which the 18th amino acid, threonine (T), of the hybrid Fc region (Hole) consisting of the amino acid sequence represented by SEQ ID NO: 13 is substituted with glutamine (Q) and the 196th amino acid, methionine (M), is substituted with leucine (L).
[0100] In the above dual specificity fusion protein, the GLP-2 analogue is GLP-2, GLP-2 A2G mutant, GLP-2 N16G_L17QThe mutant, GLP-2A2G_N16G_L17Q mutant, Glepaglutilde, or GLP-2 analogue 10 may be introduced with mutations such as amino acid substitutions, additions, or deletions to reduce binding affinity to the GLP-2 receptor in order to achieve lower activity compared to wild-type GLP-2. Alternatively, when using wild-type GLP-2, an approach to reduce binding affinity to the GLP-2 receptor can be used by shortening the length compared to the GLP-1 analogue (e.g., by inserting a longer linker peptide between the GLP-1 analogue and the Fc region). In this case, the length of the linker of the first fusion protein may be about 5 to 40 aa longer than the linker of the second fusion protein, and more specifically, 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, 25 aa, 26 aa, 27 aa, 28 aa, 29 aa, 30 aa, 31 aa, 32 aa, 33 aa, 34 aa, 35 aa, 36 aa, 37 aa, 38 aa, It can be about 39 aa or 40 aa long, and can have a certain range with any value among the above amino acid lengths as the lower limit and another value greater than that as the upper limit. In fact, the inventors of the present invention confirmed through Examples 2 to 4 that when the length of a GLP-1 analogue is designed to be longer than that of a GLP-2 analogue (by using a slightly longer glycan linker peptide or forming a GLP-1 tandem repeat), the relative activity of GLP-2 is greatly reduced, whether or not a mutation is introduced into the GLP-2 analogue.Conversely, it was confirmed that when the length of the fusion protein containing the GLP-2 analogue was made longer than that of the fusion protein containing the GLP-1 analogue by introducing a glycan linker into the GLP-2 analogue, the relative activity of the GLP-2 analogue was significantly increased.
[0101] In the above dual specificity fusion protein, the GLP-2 analogue may include an amino acid sequence represented by any one of SEQ ID NOs: 17 to 22. The peptide consisting of the amino acid sequence represented by SEQ ID NO: 18 is a human GLP-2 wild type peptide, and the human GLP-2 variant consisting of the amino acid sequence represented by SEQ ID NO: 17 is a human GLP-2 mutant in which the second amino acid, alanine, is substituted with glycine (A2G mutant or GLP-2 A2G , hereinafter referred to as 'GLP-2-2G' for convenience), is also called Teduglutide. Meanwhile, the GLP-2 variant consisting of the amino acid sequence represented by SEQ ID NO: 19 is a GLP-2 variant (GLP-2A2G_N16G_L17Q) in which not only the second amino acid, alanine (A), is mutated to glycine (G), but also the 16th amino acid, asparagine (N), is mutated to glycine (G) and the 17th amino acid, leucine (L), is mutated to glutamine (Q), and is known to maintain its function as GLP-2 while inhibiting dimerization of GLP-2 or the formation of aggregates resulting from it during recombinant production (Baker et al., J. Mol. Recognit. 25: 155-164, 2012). Optionally, a GLP-2 wild-type peptide in which the second amino acid, alanine, is substituted with glycine and the 17th amino acid, leucine, is substituted with glutamine (A2G, L17Q, SEQ ID NO: 20) can also exhibit the same function as a GLP-2 analogue composed of the amino acid sequence described in SEQ ID NO: 19, and therefore can be used as a GLP-2 analogue in the present invention.
[0102] In the above dual specificity fusion protein, the Glepaglutide may include an amino acid sequence represented by SEQ ID NO: 21.
[0103] In the above dual specificity fusion protein, the GLP-2 analogue 10 may include an amino acid sequence represented by SEQ ID NO: 22.
[0104] In the above dual specificity fusion protein, the first fusion protein may include an amino acid sequence selected from the group consisting of SEQ ID NOs: 23 to 25.
[0105] In the above dual specificity fusion protein, the second fusion protein may include an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 to 28.
[0106] In the above dual specificity fusion protein, the first fusion protein may be one in which the 10th amino acid serine of the CH3 domain in the hybrid Fc region is replaced with cysteine (C) and the 22nd amino acid threonine (T) is replaced with tryptophan (W) (Knob structure), and the second fusion protein may be one in which the 5th amino acid tyrosine (Y) of the CH3 domain in the Fc region is replaced with cysteine (C), the 22nd amino acid threonine is replaced with serine (S), the 24th amino acid leucine (L) is replaced with alanine (A), and the 63rd amino acid tyrosine (Y) is replaced with valine (V) (Hole structure), and conversely, the first fusion protein may be one in which the 5th amino acid tyrosine (Y) of the CH3 domain in the Fc region is replaced with cysteine (C) and the 22nd amino acid threonine is replaced with serine (S). The 24th amino acid, leucine (L), may be substituted with alanine (A), and the 63rd amino acid, tyrosine (Y), may be substituted with valine (V) (Hole structure), and the second fusion protein may be substituted with serine (C), the 10th amino acid of the CH3 domain in the hybrid Fc region, and the 22nd amino acid, threonine (T), may be substituted with tryptophan (W) (Knob structure).
[0107] Optionally, the first fusion protein may have threonine (T), which is the 22nd amino acid of the CH3 domain in the hybrid Fc region, replaced with tyrosine (Y), the second fusion protein may have tyrosine (Y), which is the 63rd amino acid of the CH3 domain in the hybrid Fc region, replaced with threonine (T), the second fusion protein may have tyrosine (Y), which is the 63rd amino acid of the CH3 domain in the hybrid Fc region, replaced with threonine (T), and the first fusion protein may have tyrosine (Y), which is the 63rd amino acid of the CH3 domain in the hybrid Fc region, replaced with threonine (T). However, the mutation of the 63rd amino acid may be expressed as Y86T according to the numbering rules of IMGT (international ImMunoGeneTics information system) (Lefrancet et al., Dev. Comp. Immunol., 27: 55-77, 2003), not based on the amino acid sequence of the CH3 domain of human IgG1 described in SEQ ID NO: 61. In addition to the KiH structure, various heterodimer-forming moieties, such as those described above, which are introduced into the antibody Fc region to enable heterodimer formation, may also be used.
[0108] In the above-described dual-specificity fusion protein, one or more linker peptides may be inserted between the fusion partners of the fusion protein, i.e., between the peptides or domains. That is, in the case of a dual-specificity fusion protein in which a GLP-1 analogue and a GLP-2 analogue are fused, a linker peptide may be inserted between the GLP-1 analogue and the GLP-2 analogue, and in the case of a dual-specificity fusion protein produced by dimerization of the first fusion protein and the second fusion protein, a linker peptide may be inserted between the GLP-1 analogue and the antibody Fc region within the first fusion protein, and similarly, a linker peptide may be inserted between the GLP-2 analogue and the antibody Fc region within the second fusion protein. At this time, the linker peptide may or may not include an N-glycan attachment site. The above N-glycan attachment site is intended to make it easier to confirm the formation of a heterodimer by making the sizes of the first fusion protein and the second fusion protein different, and it was confirmed that there was no significant effect on the binding affinity for GLP-1R or GLP-2R.
[0109] The above linker peptides are EPKSSDKTHTCPPCP (SEQ ID NO: 29), EPKSCDKTHTCPPCP (SEQ ID NO: 30), GGGGSGGGGSGGGGSEPKSSDKTHTCPPCP (SEQ ID NO: 31), GGGGSGGGGSGGGGSEPKSCDKTHTCPPCP (SEQ ID NO: 32), AKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECP (SEQ ID NO: 33), GGGGSGGGGSGGGGSEKEKEEQEERTHTCPPCP (SEQ ID NO: 34), GGGGSGGGGSGGGGSAKNTTAPATTRNTTRGGEEKKKEKEKEEQEERTHTCPPCP (SEQ ID NO: 35), AAGSGGGGGSGGGGSGGGGS (SEQ ID NO: 36), GGGGSGGGGSGGGGS (SEQ ID NO: 37), GGSGG (SEQ ID NO: 38), GGSGGSGGS (SEQ ID NO: 39), GGGSGG (SEQ ID NO: 40), (G4S)n (Unit: Sequence number 41, n is an integer from 1 to 10), (GGS) n (n is an integer from 1 to 10), (GS) n (n is an integer from 1 to 10), (GSSGGS) n (Unit: SEQ ID NO: 42, n is an integer from 1 to 10), KESGSVSSEQLAQFRSLD (SEQ ID NO: 43), EGKSSGSGSESKST (SEQ ID NO: 44), GSAGSAAGSGEF (SEQ ID NO: 45), (EAAAK) n (Unit: SEQ ID NO: 46, n is an integer from 1 to 10), CRRRRRREAEAC (SEQ ID NO: 47), A(EAAAK)4ALEA(EAAAK)4A (SEQ ID NO: 48), GGGGGGGG (SEQ ID NO: 49), GGGGGG (SEQ ID NO: 50), AEAAAKEAAAAKA (SEQ ID NO: 51), PAPAP (SEQ ID NO: 52), (Ala-Pro)n (n is an integer from 1 to 10), VSQTSKLTRAETVFPDV (SEQ ID NO: 53, PLGLWA (SEQ ID NO: 54), TRHRQPRGWE (SEQ ID NO: 55), AGNRVRRSVG (SEQ ID NO: 56), RRRRRRRR (SEQ ID NO: 57), GFLG (SEQ ID NO: 58), GSSGGSGSSGGSGGGDEADGSRGSQKAGVDE (SEQ ID NO: 59), or It may be GSTSGSGKPGSGEGS (SEQ ID NO: 60).
[0110] According to one aspect of the present invention, a composition comprising the dual specificity fusion protein is provided.
[0111] According to another aspect of the present invention, a pharmaceutical composition for treating a metabolic disease is provided, comprising at least one of the above-mentioned dual-specificity fusion proteins as an active ingredient.
[0112] In the pharmaceutical composition, the metabolic disease may be metabolic syndrome, obesity, diabetes, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis, or liver cirrhosis, the diabetes may be type 1 diabetes or type 2 diabetes, and the liver fibrosis may be liver fibrosis caused by the progression of chronic metabolic disorder-associated steatohepatitis.
[0113] According to another aspect of the present invention, any one of the above dual specificity fusion proteins for use in the treatment of metabolic diseases is provided.
[0114] In the above-mentioned heterospecific fusion protein, the metabolic disease may be metabolic syndrome, obesity, diabetes, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or liver cirrhosis, the diabetes may be type 1 diabetes or type 2 diabetes, and the liver fibrosis may be liver fibrosis caused by the progression of chronic metabolic disorder-associated steatohepatitis.
[0115] According to another aspect of the present invention, there is provided a use of any one of the above dual specificity fusion proteins in the manufacture of a therapeutic agent for metabolic diseases.
[0116] In the above use, the metabolic disease may be metabolic syndrome, obesity, diabetes, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or liver cirrhosis, the diabetes may be type 1 diabetes or type 2 diabetes, and the liver fibrosis may be liver fibrosis caused by the progression of chronic metabolic disorder-associated steatohepatitis.
[0117] According to another aspect of the present invention, a method for treating a metabolic disease in a subject is provided, comprising administering a therapeutically effective amount of the dual specificity fusion protein to a patient suffering from a metabolic disease.
[0118] In the above treatment method, the metabolic disease may be metabolic syndrome, obesity, diabetes, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or cirrhosis, the diabetes may be type 1 diabetes or type 2 diabetes, and the liver fibrosis may be liver fibrosis caused by the progression of chronic metabolic disorder-associated steatohepatitis.
[0119] Exendin 4, one of the GLP-1 receptor agonists, has already been proven to be effective in controlling blood sugar and weight in patients with type 2 diabetes in clinical trials (DeFronzo et al., Diabetes Care 28: 1092-1100, 2005). Therefore, the dual-specificity fusion protein according to one embodiment of the present invention can be used to treat metabolic diseases such as obesity, diabetes, and metabolic syndrome.
[0120] The composition may include a pharmaceutically acceptable carrier, and may additionally include a pharmaceutically acceptable adjuvant, excipient or diluent in addition to the carrier.
[0121] The term "pharmaceutically acceptable" as used herein refers to a composition that is physiologically tolerable and does not typically cause allergic reactions such as gastrointestinal upset, dizziness, or similar reactions when administered to humans. Examples of such carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, and preservatives may be additionally included.
[0122] Additionally, a pharmaceutical composition according to one embodiment of the present invention may be formulated using methods known in the art to enable rapid, sustained, or delayed release of the active ingredient when administered to a mammal. Formulations include powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, and sterile powder forms.
[0123] A composition according to one embodiment of the present invention may be administered via various routes, including oral, parenteral, for example, suppository, transdermal, intravenous, intraperitoneal, intramuscular, intralesional, nasal, and intrathecal administration, and may also be administered using an implantable device for sustained release or continuous or repeated release. The frequency of administration may be once a day or divided into several times within a desired range, and the administration period is not particularly limited.
[0124] A composition according to one embodiment of the present invention may be formulated in a suitable form with a commonly used pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, for example, carriers for parenteral administration such as water, suitable oils, saline solution, aqueous glucose, and glycol, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. In addition, the composition according to the present invention may appropriately include suspending agents, solubilizing agents, stabilizers, isotonic agents, preservatives, antiadsorption agents, surfactants, diluents, excipients, pH adjusters, analgesics, buffers, antioxidants, and the like, if necessary, depending on the administration method or formulation. Pharmaceutically acceptable carriers and formulations suitable for the present invention, including those exemplified above, are described in detail in the literature [Remington's Pharmaceutical Sciences, latest edition].
[0125] The dosage of the above composition to a patient will vary depending on many factors, including the patient's height, body surface area, age, the specific compound being administered, sex, time and route of administration, general health, and other medications being administered concurrently. The pharmaceutically active protein may be administered in an amount of 100 ng / kg body weight (kg) to 10 mg / kg body weight (kg), more preferably 1 to 500 μg / kg body weight, and most preferably 5 to 50 μg / kg body weight, although the dosage may be adjusted taking these factors into account.
[0126] The term "therapeutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level can be determined according to factors including the type and severity of the individual, age, sex, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The therapeutically effective amount of the composition of the present invention may be 0.1 mg / kg to 1 g / kg, more preferably 1 mg / kg to 500 mg / kg, but the effective dosage may be appropriately adjusted depending on the age, sex, and condition of the patient.
[0127] A linker peptide, typically having a flexible structure, may be inserted between the two or more proteins or domains. The above linker peptides are EPKSSDKTHTCPPCP (SEQ ID NO: 29), EPKSCDKTHTCPPCP (SEQ ID NO: 30), GGGGSGGGGSGGGGSEPKSSDKTHTCPPCP (SEQ ID NO: 31), GGGGSGGGGSGGGGSEPKSCDKTHTCPPCP (SEQ ID NO: 32), AKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECP (SEQ ID NO: 33), GGGGSGGGGSGGGGSEKEKEEQEERTHTCPPCP (SEQ ID NO: 34), GGGGSGGGGSGGGGSAKNTTAPATTRNTTRGGEEKKKEKEKEEQEERTHTCPPCP (SEQ ID NO: 35), AAGSGGGGGSGGGGSGGGGS (SEQ ID NO: 36), GGGGSGGGGSGGGGS (SEQ ID NO: 37), GGSGG (SEQ ID NO: 38), GGSGGSGGS (SEQ ID NO: 39), GGGSGG (SEQ ID NO: 40), (G4S) n (Unit: Sequence number 41, n is an integer from 1 to 10), (GGS) n (n is an integer from 1 to 10), (GS) n (n is an integer from 1 to 10), (GSSGGS) n (Unit: SEQ ID NO: 42, n is an integer from 1 to 10), KESGSVSSEQLAQFRSLD (SEQ ID NO: 43), EGKSSGSGSESKST (SEQ ID NO: 44), GSAGSAAGSGEF (SEQ ID NO: 45), (EAAAK) n(Unit: SEQ ID NO: 46, n is an integer from 1 to 10), CRRRRRREAEAC (SEQ ID NO: 47), A(EAAAK)4ALEA(EAAAK)4A (SEQ ID NO: 48), GGGGGGGG (SEQ ID NO: 49), GGGGGG (SEQ ID NO: 50), AEAAAKEAAAAKA (SEQ ID NO: 51), PAPAP (SEQ ID NO: 52), (Ala-Pro)n (n is an integer from 1 to 10), VSQTSKLTRAETVFPDV (SEQ ID NO: 53, PLGLWA (SEQ ID NO: 54), TRHRQPRGWE (SEQ ID NO: 55), AGNRVRRSVG (SEQ ID NO: 56), RRRRRRRR (SEQ ID NO: 57), GFLG (SEQ ID NO: 58), GSSGGSGSSGGSGGGDEADGSRGSQKAGVDE (SEQ ID NO: 59), or GSTSGSGKPGSGEGS (SEQ ID NO: 60) may be included.
[0128] According to another aspect of the present invention, the dual-specificity fusion protein can be produced by recombinantly expressing the first gene construct, which includes a polynucleotide encoding the first fusion protein, and the second gene construct, which includes a polynucleotide encoding the second fusion protein, by transfecting the host cell with a recombinant expression vector.
[0129] In this case, the first gene construct and the second gene construct may be expressed by being inserted into a single expression vector, or by being inserted into two separate expression vectors. In the former case, the vector may be designed so that each gene construct is operably linked to two separate regulatory sequences, or the two gene constructs may be operably linked to a single regulatory sequence, and an internal ribosome entry site (IRES) may be used to connect both gene constructs.
[0130] The term "operably linked to" as used herein means that the desired nucleic acid sequence (e.g., in an in vitro transcription / translation system or in a host cell) is linked to the regulatory sequence in such a way that its expression can occur.
[0131] The term "regulatory sequence" above includes promoters, enhancers, and other regulatory elements (e.g., polyadenylation signals). Regulatory sequences include those that direct the constitutive expression of a target nucleic acid in many host cells, those that direct the expression of a target nucleic acid only in specific tissue cells (e.g., tissue-specific regulatory sequences), and those that direct expression to be induced by a specific signal (e.g., inducible regulatory sequences). It will be understood by those skilled in the art that the design of an expression vector may vary depending on factors such as the choice of host cell to be transformed and the level of protein expression desired. The expression vector of the present invention can be introduced into a host cell to express the fusion protein. Regulatory sequences that enable expression in eukaryotic and prokaryotic cells are well known to those skilled in the art. As mentioned above, these typically include regulatory sequences responsible for transcription initiation and, optionally, a poly-A signal responsible for transcription termination and stabilization of the transcript. In addition to transcriptional regulators, additional regulatory sequences may include translational enhancers and / or native or heterologous promoter regions. For example, potential regulatory sequences that allow expression in mammalian host cells include the CMV-HSV thymidine kinase promoter, SV40, RSV (Rowe's sarcoma virus) promoter, human elongation factor 1α-promoter, glucocorticoid-inducible MMTV (Moloney mouse tumor virus) promoter, metallothionein-inducible or tetracycline-inducible promoters, or enhancers such as the CMV enhancer or SV40 enhancer. For expression in neuronal cells, it is contemplated that the neurofilament promoter, PGDF promoter, NSE promoter, PrP promoter, or thy-1 promoter may be used. The above promoters are known in the art and are described in the literature (Charron, J. Biol. Chem. 270: 25739-25745, 1995).For expression in prokaryotic cells, a number of promoters have been disclosed, including the lac promoter, the tac promoter, or the trp promoter. In addition to factors capable of initiating transcription, the regulatory sequences may also include a transcription termination signal, such as the SV40-poly-A site or the TK-poly-A site, downstream of the polynucleotide according to one embodiment of the present invention. Suitable expression vectors in the present invention are known in the art, including, but not limited to, Okayama-Berg cDNA expression vectors pcDV1 (Pharmacia), pRc / CMV, pcDNA1, pcDNA3 (Invitrogen), pSPORT1 (GIBCO BRL), pGX-27 (Patent No. 1442254), pX (Pagano et al., Science 255: 1144-1147, 1992), yeast two-hybrid vectors such as pEG202 and dpJG4-5 (Gyuris et al., Cell 75: 791-803, 1995), or prokaryotic expression vectors such as lambda gt11 or pGEX (Amersham Pharmacia). In addition to the nucleic acid molecules of the present invention, the vectors may further comprise a polynucleotide encoding a secretion signal. The above secretion signals are well known to those skilled in the art. Furthermore, depending on the expression system used, a leader sequence capable of directing the fusion protein to a cellular compartment is combined with the coding sequence of the polynucleotide according to one embodiment of the present invention, preferably a leader sequence capable of directly secreting the translated protein or its protein into the cytoplasmic periphery or extracellular medium.
[0132] In addition, the vector of the present invention can be produced by, for example, standard recombinant DNA techniques, which include, for example, blunt-end and sticky-end ligation, restriction enzyme treatment to provide appropriate termini, removal of phosphate groups by alkaline phosphatase treatment to prevent inappropriate joining, and enzymatic ligation by T4 DNA ligase. The vector of the present invention can be produced by recombining DNA encoding a signal peptide obtained by chemical synthesis or genetic recombination technology and DNA encoding the bispecific fusion protein of the present invention into a vector containing an appropriate regulatory sequence. The vector containing the regulatory sequence can be purchased or produced commercially, and in one embodiment of the present invention, pBispecific backbone vector (Genexine, Inc., Korea) or pAD15 vector was used as a backbone vector.
[0133] The above expression vector may additionally include a polynucleotide encoding a secretion signal sequence, wherein the secretion signal sequence induces secretion of a recombinant protein expressed within a cell out of the cell, and may be a tPA (tissue plasminogen activator) signal sequence, a HSV gDs (herpes simplex virus glycoprotein Ds) signal sequence, or a growth hormone signal sequence.
[0134] The expression vector according to one embodiment of the present invention may be an expression vector capable of expressing the protein in a host cell, and the expression vector may take any form, such as a plasmid vector, a viral vector, a cosmid vector, a phagemid vector, an artificial human chromosome, etc.
[0135] Hereinafter, the present invention will be described in more detail through examples and experimental examples. However, the present invention is not limited to the examples and experimental examples disclosed below, but can be implemented in various different forms. The following examples and experimental examples are provided to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the present invention of the scope of the invention.
[0136] Example: Design of a dual-specificity fusion protein
[0137] The present inventors have designed various dual-specificity fusion proteins containing both GLP-1 analogues and GLP-2 analogues, as shown in Figure 1 and Table 1 below.
[0138] In designing a dual-specificity fusion protein comprising a GLP-1 analogue and a GLP-2 analogue, GLP-1 / Exendin 4 hybrid (hereinafter, abbreviated as 'GLP-1 / Ex4 Hyb' for convenience) and its tandem repeats and GLP-2 analogue (GLP-2-2G, and mutants at positions 16 and 17 (GLP-2-2G mutant)) were used to control the activities of the GLP-1 analogue and the GLP-2 analogue, and for ease of purification, a glycan linker was used in either the first fusion protein comprising the GLP-1 analogue or the second fusion protein comprising the GLP-2 analogue, or neither of them used a glycan linker.
[0139] Example NameGLP-1 / 2 Analogue (Sequence Number)Linker (Sequence Number)Fc Region Overall Structure (Sequence Number)Comparative ExampleMG12-51. GLP-1 / Ex4 Hyb(5)2. GLP-2-2G(17)Unmodified(34)Unmodified(34)knobholeFirst fusion protein(23)Second fusion protein(26)1MG12-61. GLP-2-2G(17)2. GLP-1 / Ex4 Hyb(5)Glycan(35)Unmodified(34)holeknobSecond fusion protein(27)First fusion protein(23)2MG12-71. GLP-1 / Ex4 Hyb(5)2. GLP-2-2G mutant (19) glycan (35) unmodified (31) knobhole 1st fusion protein (24) 2nd fusion protein (28) 3MG12-8 1. GLP-1 / Ex4 Hyb (5) 2. GLP-2-2G mutant (19) unmodified (31) unmodified (31) knobhole 1st fusion protein (25) 2nd fusion protein (28) 4MG12-9 1. GLP-1 / Ex4 Hyb (5) 2. GLP-2-2G (17) unmodified (31) unmodified (34) knobhole 1st fusion protein (25) 2nd fusion protein (26)
[0140] In addition, in the case of the dual-specificity fusion protein, the Knobs-into-holes technology was applied to preferentially produce heterodimers. That is, the first fusion protein may be one in which the 10th amino acid, serine (S), of the CH3 domain in the hybrid Fc region is substituted with cysteine (C), and the 22nd amino acid, threonine (T), is substituted with tryptophan (W) (Knob), and the second fusion protein may be one in which the 5th amino acid, tyrosine (Y), of the CH3 domain in the Fc region is substituted with cysteine (C), the 22nd amino acid, threonine (T), is substituted with serine (S), the 24th amino acid, leucine (L), is substituted with alanine (A), and the 63rd amino acid, tyrosine (Y), is substituted with valine (V) (Hole). At this time, the position of the amino acid where the mutation occurred is based on the reference sequence (amino acid sequence of the human IgG1 CH3 domain of SEQ ID NO: 61). Even if additional mutations such as addition, deletion, or substitution of amino acids occur at a site unrelated to the Knobs-into-Holes structure on the CH3 domain, the amino acid corresponding to the position where the mutation occurred can be used based on the reference sequence. Optionally, the Knobs-into-Holes structure can be introduced through other amino acid mutations well known in the art. These mutations are well described in the literature (Weiet et al., Oncotarget2017, 8(31): 51037-51049; Ridgway et al., Protein Eng. 1996, 9(7): 617-621; Carter, P., J. Immunol. Methods2001, 48(1-2): 7-15; Merchant et al., Nat. Biotechnol. 1998, 16(7): 677-681).For example, a dual-specificity dimeric fusion protein can be generated through a combination of a Knob structure in which threonine, the 22nd amino acid of the CH3 domain of the first fusion protein, is substituted with tyrosine, and a Hole structure in which tyrosine, the 63rd amino acid of the CH3 domain of the second fusion protein, is substituted with threonine. The Knobs-into-Holes structure can be formed conversely by introducing a Hole structure into the first fusion protein and a Knob structure into the second fusion protein. After synthesizing the gene constructs encoding the first and second fusion proteins of the comparative dual-specificity fusion proteins designed as described above and the dual-specificity fusion proteins of Examples 1 to 4, plasmid DNA transfection was performed on HEK293F cells using the N293F vector system (Ybiologics) for temporary expression in animal cells. To prepare nucleic acid, 25 μg of plasmid DNA was mixed in 3 ml of medium, and 25 μg of 2 mg / ml PEI (Polyethylenimine, PolyPlus, USA) was added and mixed. The reaction mixture was allowed to stand at room temperature for 15 minutes and then incubated with 1x10. 6 The cells / ml were placed in 80–1000 ml of culture medium and cultured for 24 h at 120 rpm, 37°C, and 8% CO2. 24 h after DNA transfection, nutrient supplement medium components (Soytone, BD, USA) were added to a final concentration of 10 g / L. One day after transfection, the temperature was lowered to 32°C, and culture was continued for 7 days.
[0141] The supernatant obtained through the above culture was purified through the Protein A column and the secondary column. The comparative dual-specificity fusion protein (named 'MG12-5') and the dual-specificity fusion proteins of Examples 1 to 4 (named 'MG12-6', 'MG12-7', 'MG12-8', and 'MG12-9', respectively) were appropriately diluted with 4X LDS sample buffer and water for injection to prepare a final concentration of 3-10 μg / 20 μL. In the case of reducing condition samples, each substance to be analyzed was appropriately diluted with 4X LDS sample buffer, 10X reducing agent, and water for injection to prepare a final concentration of 3-10 μg / 20 μL, and heated in a 95℃ heating block for 10 minutes. 20 μL of the prepared samples were loaded into each well of the gel fixed to the pre-installed electrophoresis equipment. In the case of size markers, 3-5 μL / well was loaded. Electrophoresis was performed after setting the power supply to 120 V for 90 minutes. After electrophoresis was completed, the gel was separated, stained using a staining solution and a destaining solution, and the results were analyzed.
[0142] As confirmed in the analysis results in Figures 2a to 2d, all dual-specificity fusion proteins were observed in the region between 50 and 75 kDa under non-reducing conditions (NR) and at 37 kDa under reducing conditions (R).
[0143] In conclusion, all the bispecific fusion proteins according to the embodiments of the present invention could be normally produced and purified through SDS-PAGE, and in particular, as demonstrated through comparison of MG12-5 and GLP-2-Fc homodimers, it was confirmed that the formation of monomeric impurities was significantly reduced in the case of the bispecific biprotein applying the KiH structure compared to the case without it.
[0144] Experimental Example 1: Confirmation of in vitro activity of GLP-1 and GLP-2
[0145] The present inventors investigated the in vitro activities of the bispecific fusion protein prepared in the above examples on GLP-1 and GLP-2. Specifically, the present inventors used CHO-K1 cells (DiscoverX) stably expressing the GLP-1 receptor to evaluate the activity of the GLP-1 receptor. The GLP-1R-expressing CHO-K1 cells were subcultured and seeded in 96-well white plates at a density of 5 x 10 5 100 μL was dispensed at a quantity of 10 cells / mL and cultured in a 5% CO2 incubator at 37°C for 20-24 hours. After confirming that the cells were stably attached, the drug was prepared at a concentration three times the final concentration, and then the culture medium in the plate was removed and treated with 30 μL of the experimental reagent and 15 μL of the GLP-1 series drug. After DIRANF treatment, the reaction was performed at 37°C for 30 minutes, and a total of 75 μL of the cell lysis solution and activity evaluation reagent were added, reacted at room temperature for 1 hour, and a fluorescence reaction was induced for 4-6 hours. Through this, the GLP-1 receptor agonist binds and stimulates the CHO-K1 cells, and the amount of cAMP increases. The activity of the drug was evaluated by measuring the luciferase activity using a Spectramax M5 device and the degree of bioluminescence using a solution provided in the kit.
[0146] To evaluate the activity of the GLP-2 receptor, CHO-K1 cells (DiscoverX) stably expressing the GLP-2 receptor were used. GLP-2 activity was evaluated using the same method as above, except that GLP-2R-expressing CHO-K1 cells were used. The activity of MG12-5, a comparative example, was referenced to the values described in Korean Patent No. 10-2349718.
[0147] As a result of the analysis, as confirmed in Tables 2 and 3, with respect to GLP-1 activity, while MG12-5 of the comparative example showed 35% of the activity compared to wild-type GLP-1, the dual-specificity fusion proteins of Examples 1 to 3 of the present invention showed at least 40% of the activity compared to the wild-type GLP-1 peptide, confirming that they showed activity similar to or higher than the wild-type GLP-1, and in particular, Example 2 showed high activity of 150% or more compared to the wild-type GLP-1. In addition, with respect to GLP-2 activity, while MG12-5 of the comparative example showed 59% of the activity of the wild-type GLP-2, all of the dual-specificity fusion proteins of Examples 1 to 3 showed activity less than 50%, and in particular, the dual-specificity fusion proteins of Examples 2 and 3 showed very low activities of about 2% and 7%, respectively, compared to the wild-type GLP-2.
[0148] In vitro GLP-1 activity assay results of dual specificity fusion proteins according to embodiments of the present invention hGLP-1 Example 1 Example 2 Example 3 GLP-1 activity (Set 1) EC 50 (nM)0.691.570.350.81Relative activity compared to hGLP-1 peptide (%)1004419485GLP-1 activity (Set2)EC 50 (nM)0.891.120.570.71Relative activity compared to hGLP-1 peptide (%)10079156125
[0149] In vitro GLP-1 activity assay results of dual specificity fusion proteins according to embodiments of the present invention hGLP-2 Example 1 Example 2 Example 3 GLP-2 activity EC 50 (nM)1.182.4250.819Relative activity (%) compared to hGLP-2 peptide1004926
[0150] Experimental Example 2: Weight Loss Effect Analysis
[0151] 2-1: Analysis of the effect of a single dose
[0152] The present inventors evaluated the body weight reduction effect by a single administration of MG12-5, a comparative group, and MG12-8 according to one embodiment of the present invention. Specifically, normal 7-week-old male C57BL / 6N mice were obtained and acclimatized through free food and water supply for 1 week. After that, the mice were weighed and randomly divided into experimental groups so that the average body weights were similar. Then, MG12-5 (100 nmol / 5 mL / kg), MG12-8 (100 nmol / 5 mL / kg) prepared with MG12 formulation buffer, and a vehicle containing no drug were injected subcutaneously into the flanks of the mice. Three days after drug administration, the mice were weighed to evaluate the body weight reduction due to the drug (Fig. 3a).
[0153] As a result, as confirmed in Fig. 3b, in the vehicle administration group, it was confirmed that there was no change in body weight due to drug injection or that there was an increase. On the other hand, in the MG12-5 administration group, which is a comparative group, it was confirmed that the body weight was maintained at a very similar level to before drug administration, and in the MG12-8 administration group according to one embodiment of the present invention, it was confirmed that the body weight decreased by about 5%. Through this, it was found that the GLP-1 activity of the dual specificity fusion protein including a GLP-1 analogue and a GLP-2 analogue should be 40% or more in relative activity (%) compared to the wild-type GLP-1 peptide, or the GLP-2 activity of the fusion protein should be 50% or less in relative activity (%) compared to the wild-type GLP-2 peptide.
[0154] 2-2: Analysis of the effects of repeated administration
[0155] Next, the inventors of the present invention evaluated the weight loss effect by repeated administration of MG12-5, a comparative example, and MG12-8 according to an embodiment of the present invention. Specifically, normal 7-week-old male C57BL / 6J mice were obtained and acclimatized through free feeding and feeding for 1 week. After that, the mice were weighed and randomly divided into groups so that the average weights were similar. Then, MG12-5 (30 nmol / 5 mL / kg), MG12-8 (30 nmol / 5 mL / kg) prepared with MG12 formulation buffer, and a vehicle containing no drug were injected subcutaneously in the flanks of the mice once every two days for a total of seven times over two weeks. Then, the body weight was recorded once every two days from the first day of drug administration, and the change in body weight compared to before drug administration was expressed as a percentage (%).
[0156] As a result, as confirmed in Fig. 3d, unlike the vehicle administration group, the experimental group administered the dual-specificity fusion protein according to the comparative example and one embodiment of the present invention showed a decrease in body weight due to drug administration. However, it was confirmed that when the comparative example MG12-5 was repeatedly administered, this weight loss effect gradually returned to a normal value. On the other hand, in the case of the MG12-8 administration group according to one embodiment of the present invention, an additional weight loss effect of 5% was observed compared to the comparative example (MG12-5), and it was confirmed that the weight loss due to repeated administration was maintained compared to MG12-5.
[0157] Meanwhile, it is known that GLP-2R agonists, which are mainly used to treat short bowel syndrome, cause gallbladder hypertrophy as a side effect. Therefore, in the case of a dual-specificity fusion protein containing both a GLP-1R agonist and a GLP-2R agonist, such as the present invention, there is a possibility that such a side effect may occur if the GLP-2R agonist activity is too strong. Therefore, the inventors of the present invention measured the volume of the gallbladder of the mice the day after the last drug administration by sacrificing the mice and placing a ruler around the gallbladder and taking a photograph to measure the volume of the gallbladder.
[0158] As a result, as confirmed in Fig. 3e, the gallbladder hypertrophy phenomenon due to repeated drug administration was observed, and the gallbladder volume increased 2.3 times in the comparison group (MG12-5 administration group) compared to the vehicle administration group, but in the MG12-8 administration group according to one embodiment of the present invention, it was confirmed that the gallbladder volume was not statistically different from the vehicle administration group. Through this, it was found that the GLP-2 activity of the dual specificity fusion protein of the present invention does not exhibit toxicity when the relative activity (%) compared to the wild-type GLP-2 peptide is less than 50%.
[0159] Experimental Example 3: Analysis of the therapeutic effect of metabolic abnormality-associated steatohepatitis accompanied by intestinal leakage.
[0160] Next, the inventors of the present invention investigated the ability of Liraglutide, as a comparative group, and MG12-8 according to an embodiment of the present invention, to reduce body weight and control gut leakiness in a model animal of metabolic disorder-associated steatohepatitis accompanied by gut leakiness. Specifically, the inventors obtained 20-week-old male C57BL / 6J mice and induced overweight with a choline-deficient high-fat diet (CD-HFD). In addition, the leaky gut phenomenon was induced by cycling the treatment with a low concentration of 1% DSS (dextran sulfate sodium) for 7 days and then switching to drinking water for 10 days. Two weeks after the start of the first CD-HFD diet, Liraglutide and MG12-8 were injected subcutaneously at the given doses and dosing intervals, respectively, and the body weights were measured two weeks after the first drug administration (Fig. 4a). To confirm intestinal leakage, FITC (Fluorescein isothiocyanate)-Dextran (4 kDa) solution was administered orally 4 hours before sacrifice of mice, after which feeding was stopped, and the amount of FITC-Dextran transferred to the blood was evaluated by measuring blood fluorescence.
[0161] As a result, as confirmed in Fig. 4b, the final body weight of the vehicle administration group was confirmed to be approximately 37 g, which was more than 20% higher than the normal body weight range of 30 g. On the other hand, in the liraglutide administration group and the MG12-8 administration group according to one embodiment of the present invention, a decrease in body weight was confirmed compared to the vehicle administration group, and among these, the most effective weight loss effect was confirmed by MG12-8 according to one embodiment of the present invention.
[0162] Meanwhile, as a result of analyzing the effect on intestinal leakage, MG12-8 according to an embodiment of the present invention showed superior intestinal leakage inhibition activity compared to the control group, as confirmed in FIG. 4c. On the other hand, Liraglutide did not show intestinal leakage inhibition activity compared to the control group. Moreover, while Liraglutide, as a control group, was administered twice a day at a high dose of 55 nmol / kg, MG12-8 according to an embodiment of the present invention used a relatively low dose of 15 nmol / kg, and the administration interval was also three times a week, which is more than four times longer than Liraglutide twice a day, so it can be seen that MG12-8 is a superior substance in terms of patient convenience.
[0163] Experimental Example 4: In vivo GLP-1 activity analysis
[0164] The present inventors analyzed the in vivo GLP-1 activity of MG12-8 according to one embodiment of the present invention. To this end, the present inventors specifically secured four MG12-8 samples with different in vitro GLP-1 activities through RP-HPLC. Specifically, the four samples showed differences in the areas of peaks 1 and 3 as a result of RP-HPLC analysis. In the case of sample 1, the area of peak 1 was small, and as the sample number increased, the area of peak 1 increased, and conversely, the area of peak 3 decreased as the sample number increased (Table 4). In vitro GLP-1 activity was analyzed using HEK-GLP-1R cells (eEnzyme) stably expressing GLP-1R for the four samples with different ratios of the areas of peaks 1 and 3. Specifically, the HEK-GLP-1R cells were subcultured and seeded in 96-well black plates at a density of 3 x 10 5100 μL was dispensed at a quantity of 10 cells / mL and cultured for 20-24 hours in a 5% CO2 incubator at 37°C. After confirming that the cells were stably attached, the drug was prepared at a concentration 5 times the final concentration, and the culture medium in the plate was removed, followed by treatment with an appropriate amount of experimental reagent and GLP-1 series drugs. After reacting with the drug for 2 hours, the amount of cAMP increasing was measured by bioluminescence using the solution provided in the kit and a Spectramax M5 instrument to evaluate the activity of the drug.
[0165] RP-HPLC analysis results by sampleSample 1 peak (%)Peak 3 (%)#111.971.3#234.054.0#357.933.6#467.524.9
[0166] As a result, as confirmed in Fig. 5a, the relative GLP-1 activity was confirmed to be 100% for sample 1, approximately 200% for sample 2, approximately 300% for sample 3, and approximately 400% for sample 4. Next, the inventors of the present invention used the four samples with different in vitro GLP-1 activities as described above in animal experiments to investigate the in vivo GLP-1 activity. Specifically, for this, the inventors performed an intraperitoneal glucose tolerance test (IPGTT). The drug was administered 18 hours before the start of the IPGTT, and then the feed and bedding were removed to start fasting. Then, 18 hours after drug administration, a 20% glucose solution was administered intraperitoneally, and the changes in blood glucose over time before and after administration were observed (Fig. 5b).
[0167] As a result, as confirmed in Fig. 5c, it was confirmed that the samples showing 100-300% of the in vitro GLP-1 activity showed similar in vivo blood sugar suppression effects. Meanwhile, the sample showing 400% of the in vitro GLP-1 activity showed a higher in vivo blood sugar suppression effect than the sample showing 100%. Through this, it was found that the dual specificity fusion protein according to one embodiment of the present invention, which has 100-300% of the GLP-1 activity of the wild-type GLP-1 peptide under in vitro conditions, shows similar efficacy under in vivo conditions.
[0168] Experimental Example 5: Analysis of the Anti-Obesity Effects in a High-Fat Diet Model
[0169] 5-1: Comparative analysis of efficacy compared to conventional GLP-1R / GLP-2R dual agonists
[0170] The present inventors then sought to analyze the obesity treatment of a dual-specificity fusion protein according to an embodiment of the present invention by comparing it with previously reported GLP-1R / GLP-2R dual agonists. Specifically, to this end, the present inventors investigated the body weight loss and body composition changes caused by treatment with 30 nmol / kg of Dapiglutide mimetic and 15 and 30 nmol / kg of MG12-8 (hereinafter referred to as 'MG12' for convenience) to compare its efficacy with that of a previously known GLP-1R / GLP-2R dual agonist peptide substance (Dapiglutide mimetic). For body composition analysis, the total body fat mass and lean mass of mice were measured using a Minispec LF50 (Bruker biospin, BCA LF50) device. In addition, the rate of change in body composition before and after drug administration for 2 weeks was measured to observe the body composition changes due to the drug. To this end, 5-week-old normal C57BL / 6N male mice were obtained, and after one week of acclimatization, they were fed a 60% high-fat diet (HFD) to induce diet-induced obesity (DIO). After 16 weeks from the first HFD, an appropriately formulated dapiglutide mimetic and a dual-specificity fusion protein (MG12) according to an embodiment of the present invention were injected subcutaneously into the flanks of the mice once every two days.
[0171] As a result of analyzing the change in body weight and body composition before and after 2 weeks of drug administration, as confirmed in the left graph of Fig. 6a, it was confirmed that while about 5% of body weight was reduced by administration of 30 nmol / kg of Dapiglutide mimetic, 13% of body weight was reduced by administration of 15 nmol / kg of the dual specificity fusion protein (MG12) according to one embodiment of the present invention, and about 20% of body weight was reduced by administration of 30 nmol / kg.
[0172] In addition, after the experiment was terminated and the experimental animals were sacrificed, the weight ratio of adipose tissue and non-adipose tissue was measured. As confirmed in the graph on the right side of Fig. 6a, the normal diet and high-fat diet groups showed similar positive fat weight increase rates, but the Dapiglutide mimetic administration group and the dual-specificity fusion protein administration group according to one embodiment of the present invention showed a decrease in fat among body composition. In particular, the Dapiglutide mimetic administration group showed a decrease of about 6%, while the 15 nmol / kg MG12 administration group showed a decrease of about 18%, and the 30 nmol / kg treatment group showed a decrease in fat ratio of about 35%, indicating that the present invention is a substance with a very excellent effect in treating obesity compared to existing substances.
[0173] 5-2: Concentration-dependent effect analysis
[0174] In order to confirm whether the in vivo effect of the dual-specificity fusion protein (MG12) according to one embodiment of the present invention is concentration-dependent, the present inventors analyzed the weight loss effect in a high-fat diet obese animal model using various concentrations of the dual-specificity protein. Specifically, to evaluate the weight loss effect according to the concentration of MG12, the present inventors obtained 5-week-old normal C57BL / 6 male mice, and after one week of acclimatization, they were treated with a 60% high-fat diet (HFD) to induce diet-induced obesity (DIO). After 16 weeks from the first HFD, MG12 was prepared at 15, 30, and 60 nmol / 5 mL / kg using MG12 formulation buffer, and administered subcutaneously to the abdomen of the mice once every two days. The mice were randomly divided into groups according to their body weights so that their average body weights were similar, and the body weight change after drug administration was expressed as a percentage (%).
[0175] As a result, as confirmed in Figure 6b, both the normal diet group and the HFD diet group showed a tendency to maintain or increase body weight for 2 weeks. However, it was confirmed that the group administered MG12 showed a weight loss effect of approximately 13-25% depending on the increase in concentration, and this weight loss effect appeared to be concentration-dependent.
[0176] Next, in order to confirm whether the effect of the dual specificity fusion protein according to one embodiment of the present invention is similar to the effect of simple combined administration of GLP-1 peptide and GLP-2 peptide, the inventors separately prepared GLP-1-Fc and GLP-2-Fc, which are fusion partners of the dual specificity fusion protein according to one embodiment of the present invention, and simply combined administration (30 nmol / kg + 30 nmol / kg) and the same molar concentration (30 nmol / kg) of the dual specificity fusion protein (MG12) according to one embodiment of the present invention were administered and analyzed to compare the body weight change.
[0177] As a result, as confirmed in Fig. 6c, it was confirmed that weight loss was improved by approximately 5% more by the same dose of MG12 compared to the simple combination of GLP-1-Fc and GLP-2-Fc single substances.
[0178] 5-3: Analysis of fat-specific weight loss effects
[0179] The present inventors compared and analyzed the fat-specific weight loss effects of Trizpatide mimetic, a GLP-1R / GIPR peptide dual agonist conventionally used as an obesity treatment, and a dual-specificity fusion protein according to an embodiment of the present invention. Specifically, the present inventors obtained 5-week-old normal C57BL / 6 male mice, and after one week of acclimatization, they induced diet-induced obesity (DIO) by administering a 60% high-fat diet (HFD). Sixteen weeks after the first HFD, Tirzepatide mimetic and MG12 were prepared at 15 and 60 nmol / 5 mL / kg, respectively, using MG12 formulation buffer and administered subcutaneously. For body composition analysis, the total body fat mass and lean mass of the mice were measured using a Minispec LF50 (Bruker biospin, BCA LF50) device, and to observe changes in body composition due to the drug, the rate of change in body composition was observed before drug administration and after 2 weeks of drug administration.
[0180] As a result, as confirmed in Fig. 6d, it was confirmed that both 15 nmol / kg of Tirzepatide mimetic and 60 nmol / kg of MG12 treatment for 2 weeks showed a similar 23% body weight loss compared to the control group (vehicle administration group). In addition, as confirmed in Fig. 6e, it was confirmed that MG12 treatment showed a body fat reduction of approximately 52% compared to the 44% fat weight reduction rate by Tirzepatide mimetic. On the other hand, as confirmed in Fig. 6f, when the amount of muscle loss was measured, it was confirmed that MG12 administration group showed a decrease of only approximately 7% compared to the 14% decrease by Tirzepatide mimetic administration group.
[0181] 5-4: Analysis of visceral fat suppression effect
[0182] Next, the inventors of the present invention sought to investigate whether the fat-reducing effect of the dual-specificity fusion protein according to one embodiment of the present invention was due to the reduction of subcutaneous fat or visceral fat. Specifically, after the completion of the experiment of Experimental Example 6-3, the inventors sacrificed the experimental animals, extracted subcutaneous fat and visceral fat, measured their respective weights, and converted this into the body fat percentage of each adipose tissue by dividing it by the body weight.
[0183] As a result, as confirmed in the left graph of Fig. 6g, in the case of subcutaneous fat, both Tirzepatide mimetic and MG12 showed a tendency to have a similar or decreasing subcutaneous fat ratio compared to the control group (vehicle administration group), but it was confirmed that there was no statistical significance. On the other hand, as a result of examining the body fat ratio for visceral fat, as confirmed in the right graph of Fig. 6g, it was found that the Tirzepatide mimetic administration group decreased to the level of the control group (normal mice) compared to the vehicle administration group. In one embodiment of the present invention, the dual-specificity fusion protein administration group (MG12) had a lower visceral fat content than the Tirzepatide mimetic administration group, indicating that it is a very effective substance for reducing visceral fat in obese animals.
[0184] Experimental Example 6: Analysis of the therapeutic effects of endotoxin and liver damage.
[0185] If obesity is left untreated, it can progress to non-metabolic fatty liver disease (NAFLD) or steatohepatitis (NASH), and even liver cirrhosis, which is an irreversible liver damage disease. Therefore, the present inventors investigated whether the present inventors could suppress the increase in metabolic endotoxemia and liver damage, which are symptoms that often occur in obese animal models. After administering Tirzepatide mimetic, a GLP-1 / GIPR dual agonist at the same potent concentration, and a dual specificity fusion protein (MG12) according to an embodiment of the present invention for 2 weeks, the serum was collected and component analysis was performed. For endotoxemia analysis, a mouse LPS ELISA kit (CSB-E13066m, Cusabio) was used for analysis, and for liver damage analysis, ALT levels were measured using dry-chem equipment (DRI-CHEM NX-500, FUJI).
[0186] As a result, as confirmed in Fig. 7a, it was confirmed that the amount of lipopolysaccharide (LPS) in the serum increased due to diet-induced obesity (DIO), which induced endotoxemia. This level was not reduced when Tirzepatide mimetic was administered, but it was confirmed that it was reduced to the control level when the dual-specificity fusion protein according to an embodiment of the present invention was administered. In addition, as a result of analyzing the degree of liver damage, it was confirmed that the ALT level was significantly increased due to liver damage caused by diet-induced obesity, as confirmed in Fig. 7b. In the Tirzepatide mimetic administration group, the ALT level was reduced to half of that in the vehicle administration group, and in the dual-specificity fusion protein (MG12) administration group according to an embodiment of the present invention, it was confirmed that the ALT level reduction effect was improved to a statistically significant level compared to the Tirzepatide mimetic administration group.
[0187] Experimental Example 7: Analysis of Glucose Absorption Effects
[0188] To determine whether the bispecific fusion protein according to one embodiment of the present invention can be used for the treatment of diabetes, the inventors performed a 2-NBDG glucose uptake assay on 3T3-L1 cells, which are mouse pre-adipocytes, and L6-GLUT4myc cells, which are rat myoblasts (provided by: From the laboratory of Amira Klip, PhD, Hospital For Sick Children).
[0189] Specifically, the culture medium of 3T3-L1 adipocyte precursor cells cultured in a 24-well plate at a confluency was replaced with 24-differentiation induction medium [DMEM medium containing 10% FBS (Cytiva, USA), 1% Penicillin / Streptomycin (P / S, Cytiva, USA), 1 μM dexamethasone (DEXA, Sigma, USA), 0.5 mM 3-isobutly-1-methylxanthine (IBMX, Sigma, USA), 2 μM Rosiglitazone (Cayman, Germany), and 1 μg / mL insulin (Sigma, USA)], and then cultured under CO25% conditions for 11 days to induce differentiation into adipocytes. After differentiating cells were induced into an insulin-deficient state, the bispecific fusion protein MG12 (300 nM) according to one embodiment of the present invention and 10 μg / mL insulin were treated, and then cultured in glucose-free DMEM containing 100 μg / mL 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-Deoxyglucose (2-NDBG, Cayman, USA). Semaglutide, Tirzepatide, and Retatrutide at the same dose (300 nM) were used as positive controls. After culturing for 30 minutes, the cells were washed with glucose-free DMEM medium and incubated with lysis buffer (RIPA buffer) for 20 minutes. The fluorescence signals were measured at an excitation wavelength of 485 nm and an emission wavelength of 535 nm, respectively, using a microplate reader (SpectraMax M3, USA).
[0190] Similarly, rat L6-GLUTmyc myocytes were seeded at 2 × 10 in 24-well plates. 4Cells were seeded at a density of cells / well, and after 2 days, the medium was changed to α-MEM media (Gibco, USA) containing 1% penicillin streptomycin and 2% FBS (Cytiva, USA), and the muscle cells were differentiated for 5 days. After differentiation, the dual-specificity fusion protein MG12 (300 nM) according to one embodiment of the present invention and 10 μg / mL insulin were treated. Subsequently, 2-NDBG was treated at a concentration of 100 μg / mL for 30 minutes. After washing with α-MEM media and incubating with a lysis buffer, the intracellular 2-NBDG content was measured at 485 nm (excitation wavelength) and 535 nm (emission wavelength) using a Microplate reader (SpectraMax M3, USA).
[0191] As a result, as shown in FIG. 8, it was confirmed that the dual-specificity fusion protein (MG12) according to one embodiment of the present invention has a superior glucose uptake efficiency in differentiated adipocytes as well as muscle fibers than GLP-1-Fc or GLP-2-Fc, as well as the existing GLP-1 analog (Semaglutide) and GLP-1R / GLP-2R dual agonist (Dapiglutide).
[0192] Experimental Example 8: Animal Experiment to Verify Diabetes Treatment Efficacy
[0193] 8-1: Analysis of fasting blood glucose, intravenous insulin concentration, HOMA-IR, and HOMA-β scores
[0194] The present inventors conducted an animal experiment using diabetic model mice to determine whether a dual-specificity fusion protein according to one embodiment of the present invention not only enhances blood sugar levels but also improves insulin resistance.
[0195] Specifically, the inventors administered the indicated doses of Semaglutide, Tirzepatide, or the dual specificity fusion protein MG12-8 according to one embodiment of the present invention to 14-week-old male db / db mice (Janvier Labs, France) by subcutaneous injection once every three days for 12 weeks.
[0196] Non-fasting blood glucose levels were measured on days 25, 50, and 75 of the experiment at 25-day intervals, and blood glycated hemoglobin (HbA1c) levels were measured at monthly intervals until month 3. In addition, fasting blood glucose and blood insulin concentrations, and HOMA-IR and HOMA-β scores were calculated after the end of the experiment.
[0197] As a result, as shown in FIG. 9, it was confirmed that the dual-specificity fusion protein (MG12) according to one embodiment of the present invention has a significantly better non-fasting blood glucose lowering ability and lowers blood glycated hemoglobin (HbA1c) level at a dose of 30 nmol / kg than Semaglutide at 30 nmol / kg or Tirzepatide at 15 nmol / kg, and not only significantly lowers fasting blood glucose but also significantly increases fasting blood insulin concentration. Moreover, while neither Semaglutide at 30 nmol / kg nor Tirzepatide at 15 nmol / kg eliminated insulin resistance by exceeding 40, the dual-specificity fusion protein according to one embodiment of the present invention lowered the HOMA-IR score to the control level, and the HOMA-β score indicating beta-cell function also showed a significantly higher value compared to Semaglutide at 30 nmol / kg or Tirzepatide at 15 nmol / kg, thereby exploring the possibility of application to the treatment of not only type 2 diabetes but also type 1 diabetes.
[0198] 8-2: Histological analysis
[0199] After the experiment was completed, the inventors sacrificed the experimental animals and performed histological analysis on the pancreatic tissue.
[0200] Specifically, after the above animal experiment was completed, the experimental animals were sacrificed by general anesthesia, the pancreas was removed, fixed in 4% paraformaldehyde, embedded in paraffin, and then the tissue was cut into transverse sections (5 μm) using a microtome. The sections were stained with insulin alone, double stained for insulin and glucagon, or double stained for insulin and Ki-67. All double stainings were performed using fluorescently labeled antibodies, and then photographs were taken using a confocal laser microscope.
[0201] As a result, as confirmed in FIG. 10, the dual specificity protein according to one embodiment of the present invention not only significantly increased the pancreatic islet area, unlike the conventional diabetes treatment agents Semaglutide and Tirzepatide, but also very significantly increased the area of beta cells among the entire pancreatic islets, and in the case of alpha cells, it rather decreased, and 10,000 μm 2 The number of Ki-67-positive cells per group also significantly increased. Semaglutide, the positive control, showed a significant increase, but the effect was lower than that of MG12 at the same dose, and Tirzepatide showed no improvement at all compared to the control group.
[0202] These results suggest that the dual-specificity fusion protein according to one embodiment of the present invention is a substance with a very high protective effect on pancreatic beta cells, unlike conventional diabetes treatment agents.
[0203] As described above, the dual-specificity fusion protein according to one embodiment of the present invention was shown to be safe and very effective in reducing body weight and visceral fat content in obese animals, and was confirmed to be a very effective substance in the treatment of metabolic diseases such as diabetes, including type 1 diabetes as well as type 2 diabetes, and liver damage that occurs as conditions such as obesity persist.
[0204] While the present invention has been described with reference to the above-described embodiments and experimental examples, these are merely exemplary, and those skilled in the art will understand that various modifications and equivalent alternative embodiments are possible. Therefore, the true technical protection scope of the present invention should be determined by the technical spirit of the appended claims.
[0205] In one embodiment of the present invention, the dual specificity fusion protein can be used as a medicine, particularly as a medicine for treating metabolic diseases such as obesity, diabetes, and metabolic disorder-associated steatohepatitis.
Claims
1. In a dual specificity fusion protein in which a GLP-1 analogue and a GLP-2 analogue are fused, A dual-specificity fusion protein wherein the activity of the GLP-1 analogue is 40% or more compared to wild-type GLP-1 (human GLP-1 peptide), and the activity of the GLP-2 analogue is 50% or less compared to wild-type GLP-2 (human GLP-2 peptide).
2. A dual specificity fusion protein comprising a first fusion protein in which a GLP-1 analogue is linked to an antibody Fc region and a second fusion protein in which a GLP-2 analogue is linked to an antibody Fc region, and produced by dimerization of the first fusion protein and the second fusion protein, A dual-specificity fusion protein wherein the activity of the GLP-1 analogue is 40% or more compared to wild-type GLP-1 (human GLP-1 peptide), and the activity of the GLP-2 analogue is 50% or less compared to wild-type GLP-2 (human GLP-2 peptide).
3. In paragraph 1 or 2, The above GLP-1 analogue is a dual-specificity fusion protein having an activity under in vitro conditions that is at least 80% higher than that of wild-type GLP-1.
4. In paragraph 1 or 2, The above GLP-2 analogue is a dual specificity fusion protein having an activity under in vitro conditions that is at least 2% higher than that of wild-type GLP-2.
5. In paragraph 1 or 2, A dual-specificity fusion protein with a half-life increasing moiety.
6. In paragraph 5, A dual specificity fusion protein wherein the half-life increasing moiety is inserted between the GLP-1 analogue and the GLP-2 analogue or added to the N-terminus or C-terminus of the entire fusion protein.
7. In paragraph 5, The above half-life increasing moiety is a bispecific fusion protein, which is an antibody Fc region, PEG, XTEN, PAS (Pro-Ala-Ser), ELP (elastin-like peptide), glycine-rich HAP (homo-amino-acid polymer), GLP (gelatine-like protein), or serum albumin.
8. In paragraph 1, A dual specificity fusion protein, which is not a proglucagon or an analogue thereof in which GLP-1 and GLP-2 are linked by an intermediate peptide (intervention peptide), but a fusion protein in which the GLP-1 analogue and the GLP-2 analogue are directly linked or the two peptides are linked by a linker peptide of a different form than the intermediate peptide.
9. In paragraph 1 or 2, The above GLP-1 analogue is a bispecific fusion protein comprising GLP-1, Exendin 3, Exendin 4, GLP-1 / Exendin 4 hybrid peptide, GLP-1-XTEN, Exendin 4-XTEN, Lixisenatide, Albiglutide, Liraglutide, or Taspoglutide, or a continuous repeat of any one or more of these.
10. In paragraph 1 or 2, The above GLP-2 analogues are GLP-2, GLP-2 A2G mutant, GLP-2 N16G_L17Q mutant, GLP-2 A2G_N16G_L17Q A dual-specificity fusion protein, Glepaglutilde, or GLP-2 analogue 10.
11. In paragraph 2, The above antibody Fc region is a dual-specific fusion protein, which is a hybrid Fc region in which antibody Fc regions of two or more isotypes are mixed.
12. In paragraph 11, A dual specificity fusion protein, wherein the hybrid Fc region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 16.
13. In paragraph 2, The above antibody Fc region is a dual-specific fusion protein, which is an antibody Fc region in which a heterodimerization moiety is formed.
14. In paragraph 13, The above heterodimerization moiety is Knobs-into-Holes (KiH), KiH S-S . HA-TF, ZW1, 7.8.60, DD-KK, EW-RVT, EW-RVT S-S , a dual-specificity fusion protein, either SEED or A107.
15. A composition comprising a dual specificity fusion protein of any one of claims 1 to 14.
16. A pharmaceutical composition for treating metabolic diseases, comprising a dual specificity fusion protein of any one of claims 1 to 14 as an active ingredient.
17. In paragraph 16, The above metabolic disease is obesity, diabetes, metabolic syndrome, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or liver cirrhosis, pharmaceutical composition.
18. In paragraph 17, A pharmaceutical composition wherein the diabetes is type 1 diabetes or type 2 diabetes.
19. A dual specificity fusion protein according to any one of claims 1 to 14, used for the treatment of metabolic diseases.
20. In paragraph 19, The above metabolic diseases include obesity, diabetes, metabolic syndrome, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or cirrhosis, and dual specificity fusion proteins.
21. In paragraph 20, The above diabetes is a dual specificity fusion protein, either type 1 diabetes or type 2 diabetes.
22. Use of a dual specificity fusion protein according to any one of claims 1 to 14 for the manufacture of a therapeutic agent for metabolic diseases.
23. In paragraph 22, The above metabolic diseases are obesity, diabetes, metabolic syndrome, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or liver cirrhosis, and the use thereof.
24. In paragraph 23, The above diabetes is type 1 diabetes or type 2 diabetes, for use.
25. A method for treating a metabolic disease in an individual, comprising administering to a patient suffering from a metabolic disease a therapeutically effective amount of a dual specificity fusion protein of any one of claims 1 to 14.
26. In paragraph 25, The above metabolic diseases are obesity, diabetes, metabolic syndrome, metabolic disorder-associated fatty liver disease, metabolic disorder-associated steatohepatitis, liver fibrosis or liver cirrhosis.
27. In paragraph 26, The method wherein the above diabetes is type 1 diabetes or type 2 diabetes.
